

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/82, 9/02, 9/90, 5/10, C12Q 1/68		A1	(11) International Publication Number: WO 99/14351
			(43) International Publication Date: 25 March 1999 (25.03.99)
<p>(21) International Application Number: PCT/US98/19553</p> <p>(22) International Filing Date: 17 September 1998 (17.09.98)</p> <p>(30) Priority Data: 08/931,668 17 September 1997 (17.09.97) US</p> <p>(71) Applicant (for all designated States except US): E.I. DU PONT DE NEMOURS AND COMPANY [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).</p> <p>(72) Inventor; and</p> <p>(75) Inventor/Applicant (for US only): FADER, Gary, Michael [US/US]; 100 Woods Lane, Landenberg, PA 19350 (US).</p> <p>(74) Agent: MAJARIAN, William, R.; E.I. du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).</p>		<p>(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>	
<p>(54) Title: ISOFLAVONE BIOSYNTHETIC ENZYMES</p> <p>(57) Abstract</p> <p>This invention relates to an isolated nucleic acid fragment encoding soybean enzymes that catalyze steps in biosynthesis of isoflavones, the enzyme a member selected from the group consisting of chalcone isomerase, isoflavone reductase and vestitone reductase. The invention also relates to the construction of chimeric genes encoding all or a substantial portion of the enzymes, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the enzyme in a transformed host cell.</p>			
<pre> graph TD PA[Phenylalanine] --> C[Cinnamate] C --> pC[p-Coumarate] pC --> pCCoA[p-Coumaroyl-CoA] pCCoA --> L[Lignin] pCCoA --> CS1[Chalcone synthase] CS1 --> T1[4,2',4'-Trihydroxychalcone] CS1 --> CR1[Chalcone reductase] CR1 --> D1[7,4'-Dihydroxyflavanone] T1 --> T2[4,2',4',6'-Tetrahydroxyflavanone] T2 --> T3[5,7,4'-Trihydroxyflavanone] T3 --> F1[Flavone] T3 --> IS1[Isoflavone synthase] IS1 --> D2[Daidzein] IS1 --> G1[Genistein] D2 --> DH1[Dihydroflavanol] G1 --> DH1 DH1 --> A1[Anthocyanins] DH1 --> F2[Flavonols] DH1 --> DHP[Dihydroxypterocarpan] DH1 --> K[Ketone] DHP --> Gly1[Glycoolin I] K --> Gly1 F2 --> Gly1 A1 --> Gly1 DH1 --> Gly1 F1 --> Gly1 Gly1 --> Glyc1[Glycicin] Glyc1 --> D1 Glyc1 --> D2 Glyc1 --> G1 Glyc1 --> DH1 Glyc1 --> A1 Glyc1 --> F2 Glyc1 --> DHP Glyc1 --> K Glyc1 --> Gly1 Glyc1 --> Glyc2[Glycicin II] Glyc2 --> Glyc1 Glyc2 --> Gly1 Glyc2 --> Glyc3[Glycicin III] Glyc3 --> Glyc2 Glyc3 --> Gly1 Glyc3 --> Glyc4[Glycicin IV] Glyc4 --> Glyc3 Glyc4 --> Gly1 Glyc4 --> Glyc5[Glycicin V] Glyc5 --> Glyc4 Glyc5 --> Gly1 Glyc5 --> Glyc6[Glycicin VI] Glyc6 --> Glyc5 Glyc6 --> Gly1 Glyc6 --> Glyc7[Glycicin VII] Glyc7 --> Glyc6 Glyc7 --> Gly1 Glyc7 --> Glyc8[Glycicin VIII] Glyc8 --> Glyc7 Glyc8 --> Gly1 Glyc8 --> Glyc9[Glycicin IX] Glyc9 --> Glyc8 Glyc9 --> Gly1 Glyc9 --> Glyc10[Glycicin X] Glyc10 --> Glyc9 Glyc10 --> Gly1 Glyc10 --> Glyc11[Glycicin XI] Glyc11 --> Glyc10 Glyc11 --> Gly1 Glyc11 --> Glyc12[Glycicin XII] Glyc12 --> Glyc11 Glyc12 --> Gly1 Glyc12 --> Glyc13[Glycicin XIII] Glyc13 --> Glyc12 Glyc13 --> Gly1 Glyc13 --> Glyc14[Glycicin XIV] Glyc14 --> Glyc13 Glyc14 --> Gly1 Glyc14 --> Glyc15[Glycicin XV] Glyc15 --> Glyc14 Glyc15 --> Gly1 Glyc15 --> Glyc16[Glycicin XVI] Glyc16 --> Glyc15 Glyc16 --> Gly1 Glyc16 --> Glyc17[Glycicin XVII] Glyc17 --> Glyc16 Glyc17 --> Gly1 Glyc17 --> Glyc18[Glycicin XVIII] Glyc18 --> Glyc17 Glyc18 --> Gly1 Glyc18 --> Glyc19[Glycicin XVII] Glyc19 --> Glyc18 Glyc19 --> Gly1 Glyc19 --> Glyc20[Glycicin XVIII] Glyc20 --> Glyc19 Glyc20 --> Gly1 Glyc20 --> Glyc21[Glycicin XVII] Glyc21 --> Glyc20 Glyc21 --> Gly1 Glyc21 --> Glyc22[Glycicin XVIII] Glyc22 --> Glyc21 Glyc22 --> Gly1 Glyc22 --> Glyc23[Glycicin XVII] Glyc23 --> Glyc22 Glyc23 --> Gly1 Glyc23 --> Glyc24[Glycicin XVIII] Glyc24 --> Glyc23 Glyc24 --> Gly1 Glyc24 --> Glyc25[Glycicin XVII] Glyc25 --> Glyc24 Glyc25 --> Gly1 Glyc25 --> Glyc26[Glycicin XVIII] Glyc26 --> Glyc25 Glyc26 --> Gly1 Glyc26 --> Glyc27[Glycicin XVII] Glyc27 --> Glyc26 Glyc27 --> Gly1 Glyc27 --> Glyc28[Glycicin XVIII] Glyc28 --> Glyc27 Glyc28 --> Gly1 Glyc28 --> Glyc29[Glycicin XVII] Glyc29 --> Glyc28 Glyc29 --> Gly1 Glyc29 --> Glyc30[Glycicin XVIII] Glyc30 --> Glyc29 Glyc30 --> Gly1 Glyc30 --> Glyc31[Glycicin XVII] Glyc31 --> Glyc30 Glyc31 --> Gly1 Glyc31 --> Glyc32[Glycicin XVIII] Glyc32 --> Glyc31 Glyc32 --> Gly1 Glyc32 --> Glyc33[Glycicin XVII] Glyc33 --> Glyc32 Glyc33 --> Gly1 Glyc33 --> Glyc34[Glycicin XVIII] Glyc34 --> Glyc33 Glyc34 --> Gly1 Glyc34 --> Glyc35[Glycicin XVII] Glyc35 --> Glyc34 Glyc35 --> Gly1 Glyc35 --> Glyc36[Glycicin XVIII] Glyc36 --> Glyc35 Glyc36 --> Gly1 Glyc36 --> Glyc37[Glycicin XVII] Glyc37 --> Glyc36 Glyc37 --> Gly1 Glyc37 --> Glyc38[Glycicin XVIII] Glyc38 --> Glyc37 Glyc38 --> Gly1 Glyc38 --> Glyc39[Glycicin XVII] Glyc39 --> Glyc38 Glyc39 --> Gly1 Glyc39 --> Glyc40[Glycicin XVIII] Glyc40 --> Glyc39 Glyc40 --> Gly1 Glyc40 --> Glyc41[Glycicin XVII] Glyc41 --> Glyc40 Glyc41 --> Gly1 Glyc41 --> Glyc42[Glycicin XVIII] Glyc42 --> Glyc41 Glyc42 --> Gly1 Glyc42 --> Glyc43[Glycicin XVII] Glyc43 --> Glyc42 Glyc43 --> Gly1 Glyc43 --> Glyc44[Glycicin XVIII] Glyc44 --> Glyc43 Glyc44 --> Gly1 Glyc44 --> Glyc45[Glycicin XVII] Glyc45 --> Glyc44 Glyc45 --> Gly1 Glyc45 --> Glyc46[Glycicin XVIII] Glyc46 --> Glyc45 Glyc46 --> Gly1 Glyc46 --> Glyc47[Glycicin XVII] Glyc47 --> Glyc46 Glyc47 --> Gly1 Glyc47 --> Glyc48[Glycicin XVIII] Glyc48 --> Glyc47 Glyc48 --> Gly1 Glyc48 --> Glyc49[Glycicin XVII] Glyc49 --> Glyc48 Glyc49 --> Gly1 Glyc49 --> Glyc50[Glycicin XVIII] Glyc50 --> Glyc49 Glyc50 --> Gly1 Glyc50 --> Glyc51[Glycicin XVII] Glyc51 --> Glyc50 Glyc51 --> Gly1 Glyc51 --> Glyc52[Glycicin XVIII] Glyc52 --> Glyc51 Glyc52 --> Gly1 Glyc52 --> Glyc53[Glycicin XVII] Glyc53 --> Glyc52 Glyc53 --> Gly1 Glyc53 --> Glyc54[Glycicin XVIII] Glyc54 --> Glyc53 Glyc54 --> Gly1 Glyc54 --> Glyc55[Glycicin XVII] Glyc55 --> Glyc54 Glyc55 --> Gly1 Glyc55 --> Glyc56[Glycicin XVIII] Glyc56 --> Glyc55 Glyc56 --> Gly1 Glyc56 --> Glyc57[Glycicin XVII] Glyc57 --> Glyc56 Glyc57 --> Gly1 Glyc57 --> Glyc58[Glycicin XVIII] Glyc58 --> Glyc57 Glyc58 --> Gly1 Glyc58 --> Glyc59[Glycicin XVII] Glyc59 --> Glyc58 Glyc59 --> Gly1 Glyc59 --> Glyc60[Glycicin XVIII] Glyc60 --> Glyc59 Glyc60 --> Gly1 Glyc60 --> Glyc61[Glycicin XVII] Glyc61 --> Glyc60 Glyc61 --> Gly1 Glyc61 --> Glyc62[Glycicin XVIII] Glyc62 --> Glyc61 Glyc62 --> Gly1 Glyc62 --> Glyc63[Glycicin XVII] Glyc63 --> Glyc62 Glyc63 --> Gly1 Glyc63 --> Glyc64[Glycicin XVIII] Glyc64 --> Glyc63 Glyc64 --> Gly1 Glyc64 --> Glyc65[Glycicin XVII] Glyc65 --> Glyc64 Glyc65 --> Gly1 Glyc65 --> Glyc66[Glycicin XVIII] Glyc66 --> Glyc65 Glyc66 --> Gly1 Glyc66 --> Glyc67[Glycicin XVII] Glyc67 --> Glyc66 Glyc67 --> Gly1 Glyc67 --> Glyc68[Glycicin XVIII] Glyc68 --> Glyc67 Glyc68 --> Gly1 Glyc68 --> Glyc69[Glycicin XVII] Glyc69 --> Glyc68 Glyc69 --> Gly1 Glyc69 --> Glyc70[Glycicin XVIII] Glyc70 --> Glyc69 Glyc70 --> Gly1 Glyc70 --> Glyc71[Glycicin XVII] Glyc71 --> Glyc70 Glyc71 --> Gly1 Glyc71 --> Glyc72[Glycicin XVIII] Glyc72 --> Glyc71 Glyc72 --> Gly1 Glyc72 --> Glyc73[Glycicin XVII] Glyc73 --> Glyc72 Glyc73 --> Gly1 Glyc73 --> Glyc74[Glycicin XVIII] Glyc74 --> Glyc73 Glyc74 --> Gly1 Glyc74 --> Glyc75[Glycicin XVII] Glyc75 --> Glyc74 Glyc75 --> Gly1 Glyc75 --> Glyc76[Glycicin XVIII] Glyc76 --> Glyc75 Glyc76 --> Gly1 Glyc76 --> Glyc77[Glycicin XVII] Glyc77 --> Glyc76 Glyc77 --> Gly1 Glyc77 --> Glyc78[Glycicin XVIII] Glyc78 --> Glyc77 Glyc78 --> Gly1 Glyc78 --> Glyc79[Glycicin XVII] Glyc79 --> Glyc78 Glyc79 --> Gly1 Glyc79 --> Glyc80[Glycicin XVIII] Glyc80 --> Glyc79 Glyc80 --> Gly1 Glyc80 --> Glyc81[Glycicin XVII] Glyc81 --> Glyc80 Glyc81 --> Gly1 Glyc81 --> Glyc82[Glycicin XVIII] Glyc82 --> Glyc81 Glyc82 --> Gly1 Glyc82 --> Glyc83[Glycicin XVII] Glyc83 --> Glyc82 Glyc83 --> Gly1 Glyc83 --> Glyc84[Glycicin XVIII] Glyc84 --> Glyc83 Glyc84 --> Gly1 Glyc84 --> Glyc85[Glycicin XVII] Glyc85 --> Glyc84 Glyc85 --> Gly1 Glyc85 --> Glyc86[Glycicin XVIII] Glyc86 --> Glyc85 Glyc86 --> Gly1 Glyc86 --> Glyc87[Glycicin XVII] Glyc87 --> Glyc86 Glyc87 --> Gly1 Glyc87 --> Glyc88[Glycicin XVIII] Glyc88 --> Glyc87 Glyc88 --> Gly1 Glyc88 --> Glyc89[Glycicin XVII] Glyc89 --> Glyc88 Glyc89 --> Gly1 Glyc89 --> Glyc90[Glycicin XVIII] Glyc90 --> Glyc89 Glyc90 --> Gly1 Glyc90 --> Glyc91[Glycicin XVII] Glyc91 --> Glyc90 Glyc91 --> Gly1 Glyc91 --> Glyc92[Glycicin XVIII] Glyc92 --> Glyc91 Glyc92 --> Gly1 Glyc92 --> Glyc93[Glycicin XVII] Glyc93 --> Glyc92 Glyc93 --> Gly1 Glyc93 --> Glyc94[Glycicin XVIII] Glyc94 --> Glyc93 Glyc94 --> Gly1 Glyc94 --> Glyc95[Glycicin XVII] Glyc95 --> Glyc94 Glyc95 --> Gly1 Glyc95 --> Glyc96[Glycicin XVIII] Glyc96 --> Glyc95 Glyc96 --> Gly1 Glyc96 --> Glyc97[Glycicin XVII] Glyc97 --> Glyc96 Glyc97 --> Gly1 Glyc97 --> Glyc98[Glycicin XVIII] Glyc98 --> Glyc97 Glyc98 --> Gly1 Glyc98 --> Glyc99[Glycicin XVII] Glyc99 --> Glyc98 Glyc99 --> Gly1 Glyc99 --> Glyc100[Glycicin XVIII] Glyc100 --> Glyc99 Glyc100 --> Gly1 Glyc100 --> Glyc101[Glycicin XVII] Glyc101 --> Glyc100 Glyc101 --> Gly1 Glyc101 --> Glyc102[Glycicin XVIII] Glyc102 --> Glyc101 Glyc102 --> Gly1 Glyc102 --> Glyc103[Glycicin XVII] Glyc103 --> Glyc102 Glyc103 --> Gly1 Glyc103 --> Glyc104[Glycicin XVIII] Glyc104 --> Glyc103 Glyc104 --> Gly1 Glyc104 --> Glyc105[Glycicin XVII] Glyc105 --> Glyc104 Glyc105 --> Gly1 Glyc105 --> Glyc106[Glycicin XVIII] Glyc106 --> Glyc105 Glyc106 --> Gly1 Glyc106 --> Glyc107[Glycicin XVII] Glyc107 --> Glyc106 Glyc107 --> Gly1 Glyc107 --> Glyc108[Glycicin XVIII] Glyc108 --> Glyc107 Glyc108 --> Gly1 Glyc108 --> Glyc109[Glycicin XVII] Glyc109 --> Glyc108 Glyc109 --> Gly1 Glyc109 --> Glyc110[Glycicin XVIII] Glyc110 --> Glyc109 Glyc110 --> Gly1 Glyc110 --> Glyc111[Glycicin XVII] Glyc111 --> Glyc110 Glyc111 --> Gly1 Glyc111 --> Glyc112[Glycicin XVIII] Glyc112 --> Glyc111 Glyc112 --> Gly1 Glyc112 --> Glyc113[Glycicin XVII] Glyc113 --> Glyc112 Glyc113 --> Gly1 Glyc113 --> Glyc114[Glycicin XVIII] Glyc114 --> Glyc113 Glyc114 --> Gly1 Glyc114 --> Glyc115[Glycicin XVII] Glyc115 --> Glyc114 Glyc115 --> Gly1 Glyc115 --> Glyc116[Glycicin XVIII] Glyc116 --> Glyc115 Glyc116 --> Gly1 Glyc116 --> Glyc117[Glycicin XVII] Glyc117 --> Glyc116 Glyc117 --> Gly1 Glyc117 --> Glyc118[Glycicin XVIII] Glyc118 --> Glyc117 Glyc118 --> Gly1 Glyc118 --> Glyc119[Glycicin XVII] Glyc119 --> Glyc118 Glyc119 --> Gly1 Glyc119 --> Glyc120[Glycicin XVIII] Glyc120 --> Glyc119 Glyc120 --> Gly1 Glyc120 --> Glyc121[Glycicin XVII] Glyc121 --> Glyc120 Glyc121 --> Gly1 Glyc121 --> Glyc122[Glycicin XVIII] Glyc122 --> Glyc121 Glyc122 --> Gly1 Glyc122 --> Glyc123[Glycicin XVII] Glyc123 --> Glyc122 Glyc123 --> Gly1 Glyc123 --> Glyc124[Glycicin XVIII] Glyc124 --> Glyc123 Glyc124 --> Gly1 Glyc124 --> Glyc125[Glycicin XVII] Glyc125 --> Glyc124 Glyc125 --> Gly1 Glyc125 --> Glyc126[Glycicin XVIII] Glyc126 --> Glyc125 Glyc126 --> Gly1 Glyc126 --> Glyc127[Glycicin XVII] Glyc127 --> Glyc126 Glyc127 --> Gly1 Glyc127 --> Glyc128[Glycicin XVIII] Glyc128 --> Glyc127 Glyc128 --> Gly1 Glyc128 --> Glyc129[Glycicin XVII] Glyc129 --> Glyc128 Glyc129 --> Gly1 Glyc129 --> Glyc130[Glycicin XVIII] Glyc130 --> Glyc129 Glyc130 --> Gly1 Glyc130 --> Glyc131[Glycicin XVII] Glyc131 --> Glyc130 Glyc131 --> Gly1 Glyc131 --> Glyc132[Glycicin XVIII] Glyc132 --> Glyc131 Glyc132 --> Gly1 Glyc132 --> Glyc133[Glycicin XVII] Glyc133 --> Glyc132 Glyc133 --> Gly1 Glyc133 --> Glyc134[Glycicin XVIII] Glyc134 --> Glyc133 Glyc134 --> Gly1 Glyc134 --> Glyc135[Glycicin XVII] Glyc135 --> Glyc134 Glyc135 --> Gly1 Glyc135 --> Glyc136[Glycicin XVIII] Glyc136 --> Glyc135 Glyc136 --> Gly1 Glyc136 --> Glyc137[Glycicin XVII] Glyc137 --> Glyc136 Glyc137 --> Gly1 Glyc137 --> Glyc138[Glycicin XVIII] Glyc138 --> Glyc137 Glyc138 --> Gly1 Glyc138 --> Glyc139[Glycicin XVII] Glyc139 --> Glyc138 Glyc139 --> Gly1 Glyc139 --> Glyc140[Glycicin XVIII] Glyc140 --> Glyc139 Glyc140 --> Gly1 Glyc140 --> Glyc141[Glycicin XVII] Glyc141 --> Glyc140 Glyc141 --> Gly1 Glyc141 --> Glyc142[Glycicin XVIII] Glyc142 --> Glyc141 Glyc142 --> Gly1 Glyc142 --> Glyc143[Glycicin XVII] Glyc143 --> Glyc142 Glyc143 --> Gly1 Glyc143 --> Glyc144[Glycicin XVIII] Glyc144 --> Glyc143 Glyc144 --> Gly1 Glyc144 --> Glyc145[Glycicin XVII] Glyc145 --> Glyc144 Glyc145 --> Gly1 Glyc145 --> Glyc146[Glycicin XVIII] Glyc146 --> Glyc145 Glyc146 --> Gly1 Glyc146 --> Glyc147[Glycicin XVII] Glyc147 --> Glyc146 Glyc147 --> Gly1 Glyc147 --> Glyc148[Glycicin XVIII] Glyc148 --> Glyc147 Glyc148 --> Gly1 Glyc148 --> Glyc149[Glycicin XVII] Glyc149 --> Glyc148 Glyc149 --> Gly1 Glyc149 --> Glyc150[Glycicin XVIII] Glyc150 --> Glyc149 Glyc150 --> Gly1 Glyc150 --> Glyc151[Glycicin XVII] Glyc151 --> Glyc150 Glyc151 --> Gly1 Glyc151 --> Glyc152[Glycicin XVIII] Glyc152 --> Glyc151 Glyc152 --> Gly1 Glyc152 --> Glyc153[Glycicin XVII] Glyc153 --> Glyc152 Glyc153 --> Gly1 Glyc153 --> Glyc154[Glycicin XVIII] Glyc154 --> Glyc153 Glyc154 --> Gly1 Glyc154 --> Glyc155[Glycicin XVII] Glyc155 --> Glyc154 Glyc155 --> Gly1 Glyc155 --> Glyc156[Glycicin XVIII] Glyc156 --> Glyc155 Glyc156 --> Gly1 Glyc156 --> Glyc157[Glycicin XVII] Glyc157 --> Glyc156 Glyc157 --> Gly1 Glyc157 --> Glyc158[Glycicin XVIII] Glyc158 --> Glyc157 Glyc158 --> Gly1 Glyc158 --> Glyc159[Glycicin XVII] Glyc159 --> Glyc158 Glyc159 --> Gly1 Glyc159 --> Glyc160[Glycicin XVIII] Glyc160 --> Glyc159 Glyc160 --> Gly1 Glyc160 --> Glyc161[Glycicin XVII] Glyc161 --> Glyc160 Glyc161 --> Gly1 Glyc161 --> Glyc162[Glycicin XVIII] Glyc162 --> Glyc161 Glyc162 --> Gly1 Glyc162 --> Glyc163[Glycicin XVII] Glyc163 --> Glyc162 Glyc163 --> Gly1 Glyc163 --> Glyc164[Glycicin XVIII] Glyc164 --> Glyc163 Glyc164 --> Gly1 Glyc164 --> Glyc165[Glycicin XVII] Glyc165 --> Glyc164 Glyc165 --> Gly1 Glyc165 --> Glyc166[Glycicin XVIII] Glyc166 --> Glyc165 Glyc166 --> Gly1 Glyc166 --> Glyc167[Glycicin XVII] Glyc167 --> Glyc166 Glyc167 --> Gly1 Glyc167 --> Glyc168[Glycicin XVIII] Glyc168 --> Glyc167 Glyc168 --> Gly1 Glyc168 --> Glyc169[Glycicin XVII] Glyc169 --> Glyc168 Glyc169 --> Gly1 Glyc169 --> Glyc170[Glycicin XVIII] Glyc170 --> Glyc169 Glyc170 --> Gly1 Glyc170 --> Glyc171[Glycicin XVII] Glyc171 --> Glyc170 Glyc171 --> Gly1 Glyc171 --> Glyc172[Glycicin XVIII] Glyc172 --> Glyc171 Glyc172 --> Gly1 Glyc172 --> Glyc173[Glycicin XVII] Glyc173 --> Glyc172 Glyc173 --> Gly1 Glyc173 --> Glyc174[Glycicin XVIII] Glyc174 --> Glyc173 Glyc174 --> Gly1 Glyc174 --> Glyc175[Glycicin XVII] Glyc175 --> Glyc174 Glyc175 --> Gly1 Glyc175 --> Glyc176[Glycicin XVIII] Glyc176 --> Glyc175 Glyc176 --> Gly1 Glyc176 --> Glyc177[Glycicin XVII] Glyc177 --> Glyc176 Glyc177 --> Gly1 Glyc177 --> Glyc178[Glycicin XVIII] Glyc178 --> Glyc177 Glyc178 --> Gly1 Glyc178 --> Glyc179[Glycicin XVII] Glyc179 --> Glyc178 Glyc179 --> Gly1 Glyc179 --> Glyc180[Glycicin XVIII] Glyc180 --> Glyc179 Glyc180 --> Gly1 Glyc180 --> Glyc181[Glycicin XVII] Glyc181 --> Glyc180 Glyc181 --> Gly1 Glyc181 --> Glyc182[Glycicin XVIII] Glyc182 --> Glyc181 Glyc182 --> Gly1 Glyc182 --> Glyc183[Glycicin XVII] Glyc183 --> Glyc182 Glyc183 --> Gly1 Glyc183 --> Glyc184[Glycicin XVIII] Glyc184 --> Glyc183 Glyc184 --> Gly1 Glyc184 --> Glyc185[Glycicin XVII] Glyc185 --> Glyc184 Glyc185 --> Gly1 Glyc185 --> Glyc186[Glycicin XVIII] Glyc186 --> Glyc185 Glyc186 --> Gly1 Glyc186 --> Glyc187[Glycicin XVII] Glyc187 --> Glyc186 Glyc187 --> Gly1 Glyc187 --> Glyc188[Glycicin XVIII] Glyc188 --> Glyc187 Glyc188 --> Gly1 Glyc188 --> Glyc189[Glycicin XVII] Glyc189 --> Glyc188 Glyc189 --> Gly1 Glyc189 --> Glyc190[Glycicin XVIII] Glyc190 --> Glyc189 Glyc190 --> Gly1 Glyc190 --> Glyc191[Glycicin XVII] Glyc191 --> Glyc190 Glyc191 --> Gly1 Glyc191 --> Glyc192[Glycicin XVIII] Glyc192 --> Glyc191 Glyc192 --> Gly1 Glyc192 --> Glyc193[Glycicin XVII] Glyc193 --> Glyc192 Glyc193 --> Gly1 Glyc193 --> Glyc194[Glycicin XVIII] Glyc194 --> Glyc193 Glyc194 --> Gly1 Glyc194 --> Glyc195[Glycicin XVII] Glyc195 --> Glyc194 Glyc195 --> Gly1 Glyc195 --> Glyc196[Glycicin XVIII] Glyc196 --> Glyc195 Glyc196 --> Gly1 Glyc196 --> Glyc197[Glycicin XVII] Glyc197 --> Glyc196 Glyc197 --> Gly1 Glyc197 --> Glyc198[Glycicin XVIII] Glyc198 --> Glyc197 Glyc198 --> Gly1 Glyc198 --> Glyc199[Glycicin XV</pre>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

TITLE

ISOFLAVONE BIOSYNTHETIC ENZYMES

FIELD OF THE INVENTION

5 This invention is in the field of plant molecular biology. More specifically, this invention pertains to nucleic acid fragments encoding enzymes involved in isoflavone biosynthesis in plants and seeds.

BACKGROUND OF THE INVENTION

10 Isoflavones represent a class of secondary metabolites produced in legumes by the phenylpropanoid metabolic pathway. The biosynthetic pathway for free isoflavones and their relationship with several other classes of phenylpropanoids is presented in Figure 1. Many of the enzymes involved in the synthesis of isoflavones in soybean have been identified and the genes in the pathway from phenylalanine ammonia lyase to chalcone synthase and chalcone reductase have been cloned. However, remaining soybean genes involved in synthesis (chalcone isomerase and isoflavone synthase), further metabolism (isoflavone reductase and vestitone reductase), and branch points of the isoflavone pathway that could compete for substrates (flavanone hydroxylase and flavonol synthase) heretofore have not been available.

15

20 Free isoflavones rarely accumulate to high levels in soybeans. Instead they are usually conjugated to carbohydrates or organic acids. Soybean seeds contain three types of isoflavones in four different forms: the aglycones daidzein, genistein, and glycitein; the glucosides diadzin, genistin, and glycitin; the acetylglucosides 6"-O-acetyl daidzin, 6"-O-acetylgenistin, and 6"-O-acetylglycitin; and the malonylglucosides 6"-O-malonyldaidzin, 6"-O-malonylgenistin, and 6"-O-malonylglycitin. It has been reported that the isoflavones found in soybean seeds possess antihemolytic (Naim, M. et al. (1976) *J. Agric. Food Chem.* 24:1174-1177), antifungal (Naim, M. et al. (1974) *J. Agr. Food Chem.* 22:806-810), oestrogenic (Price, K.R. and Fenwick, G.R. (1985) *Food Addit. Contam.* 2:73-106), tumor suppressing (Messina, M. and Barnes, S. (1991) *J. Natl. Cancer Inst.* 83:541-546; Peterson, G. et al. (1991) *Biochem. Biophys. Res. Commun.* 179:661-667), hypolipidemic (Mathur, K. et al. (1964) *J. Nutr.* 84:201-204), and serum cholesterol lowering (Sharma, R.D. (1979) *Lipids* 14:535-540) effects. These epidemiological studies indicate that when isoflavone levels are high in soybean seeds and in the subsequent commercial protein products made from the seeds, the dietary intake of these products provide many health benefits.

25

30 The content of isoflavones in soybean seeds, however, is quite variable and is affected by both genetics and environmental conditions such as growing location and temperature during seed fill (Tsukamoto, C. et al. (1995) *J. Agric. Food Chem.* 43:1184-1192; Wang, H. and Murphy, P. A. (1994) *J. Agric. Food Chem.* 42:1674-1677). In addition, isoflavone content in legumes can be stress-induced by pathogenic attack, wounding, high UV light exposure, and pollution (Dixon, R. A. and Paiva, N. L. (1995) *The Plant Cell* 7:1085-1097).

35

To date, it has been difficult to develop soybean lines with consistently high levels of isoflavones; moreover, lines reported to be low in isoflavone content produced normal levels of isoflavones when grown under standard cultural conditions (Kitamura, K. et al. (1991) *Jap. J. Breed.* 41:651-654). The isolation and cloning of genes associated with synthesis and metabolism of isoflavones in soybean will afford the application of molecular techniques to achieve stable, high level accumulation of isoflavones.

SUMMARY OF THE INVENTION

The instant invention relates to isolated nucleic acid fragments encoding plant enzymes involved in isoflavone biosynthesis. Specifically, this invention concerns isolated nucleic acid fragments encoding the following soybean enzymes that catalyze steps in the biosynthesis of isoflavones from phenylalanine: chalcone isomerase, isoflavone reductase and vestitone reductase. In addition, this invention relates to nucleic acid fragments that are complementary to nucleic acid fragments encoding the listed soybean biosynthetic enzymes.

In another embodiment, the instant invention relates to chimeric genes encoding the isoflavone biosynthetic acid enzymes listed above or to chimeric genes that comprise nucleic acid fragments that are complementary to the nucleic acid fragments encoding the enzymes, operably linked to suitable regulatory sequences, wherein expression of the chimeric genes results in production of levels of isoflavone biosynthetic enzymes in transformed host cells that are altered (i.e., increased or decreased) from the levels produced in untransformed host cells.

In a further embodiment, the instant invention concerns a transformed host cell comprising in its genome a chimeric gene encoding an isoflavone biosynthetic enzyme operably linked to suitable regulatory sequences, the enzyme selected from the group consisting of chalcone isomerase, isoflavone reductase and vestitone reductase. Expression of the chimeric gene results in production of altered levels of the biosynthetic enzyme in the transformed host cell. The transformed host cell can be of eukaryotic or prokaryotic origin, and include cells derived from higher plants and microorganisms. The invention also includes transformed plants that arise from transformed host cells of higher plants, and seeds derived from such transformed plants.

An additional embodiment of the instant invention concerns a method of altering the level of expression of a plant isoflavone biosynthetic enzyme in a transformed host cell comprising: a) transforming a host cell with a chimeric gene comprising a nucleic acid fragment encoding a soybean isoflavone biosynthetic enzyme selected from the group consisting of chalcone isomerase, isoflavone reductase and vestitone reductase, operably linked to suitable regulatory sequences; and b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in production of altered levels of an isoflavone biosynthetic enzyme in the transformed host cell.

An additional embodiment of the instant invention concerns a method for obtaining a nucleic acid fragment encoding all or substantially all of an amino acid sequence encoding a plant chalcone isomerase, isoflavone reductase and vestitone reductase.

5 BRIEF DESCRIPTION OF THE
DRAWINGS AND SEQUENCE DESCRIPTIONS

The invention can be more fully understood from the following detailed description and the accompanying drawings and sequence descriptions which form a part of this application.

10 Figure 1 depicts the phenylpropanoid metabolic pathway illustrating the biosynthesis of isoflavones.

Figure 2 shows a comparison of the amino acid sequences of the *Pueraria lobata* chalcone flavanone isomerase (D63577) and the instant soybean chalcone isomerase (ssm.pk0013.e3).

15 Figure 3 shows a comparison of the amino acid sequences of the isoflavone reductase homolog from *Lupinus albus* (P52581) and the instant soybean isoflavone reductase (se3.pk0034.g5).

Figure 4 shows a comparison of the amino acid sequences of the *Medicago sativa* vestitone reductase (U28213) and the instant soybean vestitone reductase (sre.pk0016.c8).

20 The following sequence descriptions and sequences listings attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825.

SEQ ID NO:1 is the nucleotide sequence comprising part of the cDNA insert in clone ssm.pk0013.e3 encoding a soybean chalcone isomerase.

25 SEQ ID NO:2 is the deduced amino acid sequence of a soybean chalcone isomerase derived from the nucleotide sequence of SEQ ID NO:1.

SEQ ID NO:3 is the amino acid sequence encoding the *Pueraria lobata* chalcone flavanone isomerase having DDJB Accession No. D63577.

SEQ ID NO:4 is the nucleotide sequence comprising part of the cDNA insert in clone se3.pk0034.g5 encoding a soybean isoflavone reductase.

30 SEQ ID NO:5 is the deduced amino acid sequence of a soybean isoflavone reductase derived from the nucleotide sequence of SEQ ID NO:4.

SEQ ID NO:6 is the amino acid sequence encoding the isoflavone reductase homolog from *Lupinus albus* having SWISS-PROT Accession No. P52581.

35 SEQ ID NO:7 is the nucleotide sequence comprising part of the cDNA insert in clone sre.pk0016.c8 encoding a soybean vestitone reductase.

SEQ ID NO:8 is the deduced amino acid sequence of a soybean vestitone reductase derived from the nucleotide sequence of SEQ ID NO:7.

SEQ ID NO:9 is the amino acid sequence encoding the *Medicago sativa* vestitone reductase having GenBank Accession No. U28213.

5 The Sequence Descriptions contain the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUB standards described in *Nucleic Acids Research* 13:3021-3030 (1985) and in the *Biochemical Journal* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

DETAILED DESCRIPTION OF THE INVENTION

10 The instant invention discloses the amino acid sequence for three enzymes involved in the synthesis and metabolism of isoflavones in soybeans: chalcone isomerase, isoflavone reductase and vestitone reductase. As these genes code for enzymes nearer to the desired isoflavones in the phenylpropanoid pathway (see Fig. 1), they may be more useful in manipulating isoflavone content without affecting other portions of the phenylpropanoid 15 pathway associated with lignin, anthocyanin or flavonol biosynthesis.

15 In the context of this disclosure, a number of terms shall be utilized. As used herein, an "isolated nucleic acid fragment" is a polymer of RNA or DNA that is single- or double-stranded, optionally containing synthetic, non-natural or altered nucleotide bases. An isolated nucleic acid fragment in the form of a polymer of DNA may be comprised of one or 20 more segments of cDNA, genomic DNA or synthetic DNA.

25 As used herein, "substantially similar" refers to nucleic acid fragments wherein changes in one or more nucleotide bases results in substitution of one or more amino acids, but do not affect the functional properties of the protein encoded by the DNA sequence. "Substantially similar" also refers to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid fragment to mediate alteration 30 of gene expression by antisense or co-suppression technology. "Substantially similar" also refers to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially affect the functional properties of the resulting transcript vis-à-vis the ability to mediate alteration of gene expression by antisense or co-suppression technology or alteration of the functional properties of the resulting protein molecule. It is therefore understood that the invention encompasses more than the specific exemplary sequences.

35 For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than the entire coding region of a gene, and by nucleic acid fragments that do not share 100% identity with the gene to be suppressed. Moreover, alterations in a gene which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded protein, are well known in the art. For example, a

codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the protein molecule would also not be expected to alter the activity of the protein. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Moreover, the skilled artisan recognizes that substantially similar sequences encompassed by this invention are also defined by their ability to remain hybridized under conditions of moderate stringency (washes in 1 X SSC, 0.1% SDS, at 55°C), with the sequences exemplified herein. Preferred substantially similar nucleic acid fragments of the instant invention are those nucleic acid fragments whose DNA sequences are 80% identical to the DNA sequence of the nucleic acid fragments reported herein. More preferred nucleic acid fragments are 90% identical to the identical to the DNA sequence of the nucleic acid fragments reported herein. Most preferred are nucleic acid fragments that are 95% identical to the DNA sequence of the nucleic acid fragments reported herein. Determination of percent identity of any DNA or protein sequences is performed by application of the comparison algorithm of Hein (*Methods in Enzymology* 183:626-645 (1990)), and using the following values for the variable parameters: GAP PENALTY=11, GAP LENGTH PENALTY=3, and for the case of pairwise alignments KTUPLE 6.

A "substantial portion" of an amino acid or nucleotide sequence comprises enough of the amino acid sequence of a polypeptide or the nucleotide sequence of a gene to afford putative identification of that polypeptide or gene, either by manual evaluation of the sequence by one skilled in the art, or by computer-automated sequence comparison and identification using algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul, S. F., et al., (1993) *J. Mol. Biol.* 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/). In general, a sequence of ten or more contiguous amino acids or thirty or more nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene specific oligonucleotide probes comprising 20-30 contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12-15 bases may be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers. Accordingly, a "substantial portion" of a nucleotide sequence comprises enough of the sequence to afford specific identification and/or isolation of a

nucleic acid fragment comprising the sequence. The instant specification teaches partial or complete amino acid and nucleotide sequences encoding one or more particular plant proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art. Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

“Codon degeneracy” refers to divergence in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment that encodes all or a substantial portion of the amino acid sequence encoding the isoflavone biosynthetic enzymes as set forth in SEQ ID NOs:2, 5 and 8. The skilled artisan is well aware of the “codon-bias” exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a gene for improved expression in a host cell, it is desirable to design the gene such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

“Synthetic genes” can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form gene segments which are then enzymatically assembled to construct the entire gene. “Chemically synthesized”, as related to a sequence of DNA, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of DNA may be accomplished using well established procedures, or automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly, the genes can be tailored for optimal gene expression based on optimization of nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

“Gene” refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. “Native gene” refers to a gene as found in nature with its own regulatory sequences. “Chimeric gene” refers any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. “Endogenous gene” refers to a native gene in its natural location in the genome of an organism. A “foreign” gene refers to a gene not normally found in the host organism, but

that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A "transgene" is a gene that has been introduced into the genome by a transformation procedure.

"Coding sequence" refers to a DNA sequence that codes for a specific amino acid sequence. "Regulatory sequences" refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

"Promoter" refers to a DNA sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an "enhancer" is a DNA sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic DNA segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a gene to be expressed in most cell types at most times are commonly referred to as "constitutive promoters". New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and Goldberg, (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of different lengths may have identical promoter activity.

The "translation leader sequence" refers to a DNA sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner, R. and Foster, G.D. (1995) *Molecular Biotechnology* 3:225).

The "3' non-coding sequences" refer to DNA sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al., (1989) *Plant Cell* 1:671-680.

“RNA transcript” refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from posttranscriptional processing of the primary transcript and is referred to as the mature RNA. “Messenger RNA (mRNA)” refers to the RNA that is without introns and that can be translated into protein by the cell. “cDNA” refers to a double-stranded DNA that is complementary to and derived from mRNA. “Sense” RNA refers to RNA transcript that includes the mRNA and so can be translated into protein by the cell. “Antisense RNA” refers to a RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (U.S. Pat. No. 5,107,065). The complementarity of an antisense RNA may be with any part of the specific gene transcript, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. “Functional RNA” refers to antisense RNA, ribozyme RNA, or other RNA that is not translated yet has an effect on cellular processes.

15 The term “operably linked” refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

20 The term “expression”, as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide. “Antisense inhibition” refers to the production of antisense RNA transcripts capable of suppressing the expression of the target protein. “Overexpression” refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. “Co-suppression” refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Pat. No. 5,231,020).

30 “Altered levels” refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms. “Mature” protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. “Precursor” protein refers to the primary product of translation of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

35 A “chloroplast transit peptide” is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the chloroplast or other plastid types

present in the cell in which the protein is made. "Chloroplast transit sequence" refers to a nucleotide sequence that encodes a chloroplast transit peptide. A "signal peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the secretory system (Chrispeels, J.J., (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53). If the protein is to be directed to a vacuole, a vacuolar targeting signal (*supra*) can further be added, or if to the endoplasmic reticulum, an endoplasmic reticulum retention signal (*supra*) may be added. If the protein is to be directed to the nucleus, any signal peptide present should be removed and instead a nuclear localization signal included (Raikhel (1992) *Plant Phys.* 100:1627-1632).

"Transformation" refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" organisms. Examples of methods of plant transformation include Agrobacterium-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 153:277) and particle-accelerated or "gene gun" transformation technology (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Pat. No. 4,945,050).

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook, J., Fritsch, E.F. and Maniatis, T. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter "Maniatis").

Nucleic acid fragments encoding several soybean isoflavone biosynthetic enzymes have been isolated and identified by comparison of random plant cDNA sequences to public databases containing nucleotide and protein sequences using the BLAST algorithms well known to those skilled in the art. Table 1 lists the isoflavone biosynthetic enzymes that are described herein, and the designation of the cDNA clones that comprise the nucleic acid fragments encoding these enzymes.

TABLE 1
Isoflavone Biosynthetic Enzymes

Enzyme	Clone
chalcone isomerase	ssm.pk0013.e3
isoflavone reductase	se3.pk0034.g5
vestitone reductase	sre.pk0016.c8

The nucleic acid fragments of the instant invention may be used to isolate cDNAs and genes encoding homologous enzymes from the same or other plant species. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to, methods of nucleic acid hybridization, and methods of DNA and RNA amplification as exemplified by various uses

of nucleic acid amplification technologies (e.g., polymerase chain reaction, ligase chain reaction).

For example, genes encoding other isoflavone biosynthetic enzymes, either as cDNAs or genomic DNAs, could be isolated directly by using all or a portion of the instant nucleic acid fragments as DNA hybridization probes to screen libraries from any desired plant employing methodology well known to those skilled in the art. Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis). Moreover, the entire sequences can be used directly to synthesize DNA probes by methods known to the skilled artisan such as random primers 5 DNA labeling, nick translation, or end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In addition, specific primers can be designed and used to amplify a part of or full-length of the instant sequences. The resulting amplification 10 products can be labeled directly during amplification reactions or labeled after amplification reactions, and used as probes to isolate full length cDNA or genomic fragments under 15 conditions of appropriate stringency.

In addition, two short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols to amplify longer nucleic acid fragments encoding homologous genes from DNA or RNA. The polymerase chain reaction may also be 20 performed on a library of cloned nucleic acid fragments wherein the sequence of one primer is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA precursor encoding plant genes. Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow 25 the RACE protocol (Frohman et al., (1988) *PNAS USA* 85:8998) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed from the instant 30 sequences. Using commercially available 3' RACE or 5' RACE systems (BRL), specific 3' or 5' cDNA fragments can be isolated (Ohara et al., (1989) *PNAS USA* 86:5673; Loh et al., (1989) *Science* 243:217). Products generated by the 3' and 5' RACE procedures can be 35 combined to generate full-length cDNAs (Frohman, M.A. and Martin, G.R., (1989) *BioTechniques* 1:165).

Availability of the instant nucleotide and deduced amino acid sequences facilitates 35 immunological screening cDNA expression libraries. Synthetic peptides representing portions of the instant amino acid sequences may be synthesized. These peptides can be used to immunize animals to produce polyclonal or monoclonal antibodies with specificity for peptides or proteins comprising the amino acid sequences. These antibodies can be then be used to screen cDNA expression libraries to isolate full-length cDNA clones of interest (Lerner, R.A. (1984) *Adv. Immunol.* 36:1; Maniatis).

The nucleic acid fragments of the instant invention may be used to create transgenic plants in which expression of nucleic acid sequences (or their complements) encoding the disclosed biosynthetic enzymes result in levels of the corresponding endogenous enzymes that are higher or lower than normal. Alternatively, expression of the instant nucleic acid sequences may result in the production of the encoded enzymes in cell types or developmental stages in which they are not normally found. Either strategy would have the effect of altering the level of isoflavones.

For example, overexpression of chalcone isomerase may result in an increase in isoflavone content in legumes, and anthocyanin, flavone and flavanols in other plant species. 10 Chalcone isomerase overexpression may result in an increase in levels of 7,4'-dihydroxy-flavone and 5,7,4'-trihydroxyflavone, precursors in the biosynthetic pathways leading to isoflavone, flavone and dihydroflavonol (which upon continuation leads to anthocyanin and flavanols) synthesis (see Fig. 1). Increased isoflavone content in legumes has been shown to be associated with beneficial health effects in humans. In contrast, certain soy food products 15 would benefit from lower levels of isoflavone, flavone, anthocyanins and flavanols due to adverse effects on flavor. Accordingly, in some applications, decreased chalcone isomerase activity, induced by antisense suppression or co-suppression of gene expression, may be desirable.

Likewise, overexpression of isoflavone reductase and vestitone reductase could lead to 20 increased metabolism of isoflavones in legumes, resulting in lower levels of isoflavones. Conversely, inhibition of expression of genes encoding isoflavone reductase and vestitone reductase may result in increased isoflavone content by reducing isoflavone metabolism by these enzymes.

Overexpression of the biosynthetic enzymes of the instant invention may be 25 accomplished by first constructing chimeric genes in which the coding regions are operably linked to promoters capable of directing expression of a gene in the desired tissues at the desired stage of development. For reasons of convenience, the chimeric genes may comprise promoter sequences and translation leader sequences derived from the same genes. 3' Non-coding sequences encoding transcription termination signals may also be provided. The 30 instant chimeric genes may also comprise one or more introns in order to facilitate gene expression.

Plasmid vectors comprising the instant chimeric genes can then be constructed. The choice of plasmid vector is dependent upon the method that will be used to transform host plants. The skilled artisan is well aware of the genetic elements that must be present on the 35 plasmid vector in order to successfully transform, select and propagate host cells containing the chimeric gene. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al., (1985) *EMBO J.* 4:2411-2418; De Almeida et al., (1989) *Mol. Gen. Genetics* 218:78-86),

and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

5 For some applications it may be useful to direct the instant biosynthetic enzymes to different cellular compartments, or to facilitate their secretion from the cell. It is thus envisioned that the chimeric genes described above may be further supplemented by altering the coding sequences to encode enzymes with appropriate intracellular targeting sequences such as transit sequences (Keegstra, K. (1989) *Cell* 56:247-253), signal sequences or 10 sequences encoding endoplasmic reticulum localization (Chrispeels, J. J., (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53), or nuclear localization signals (Raikhel, N. (1992) *Plant Phys.* 100:1627-1632) added and/or with targeting sequences that are already present removed. While the references cited give examples of each of these, the list is not exhaustive and more targeting signals of utility may be discovered in the future.

15 It may also be desirable to reduce or eliminate expression of the genes encoding isoflavone biosynthetic enzymes in plants for some applications. In order to accomplish this, chimeric genes designed for co-suppression of the instant biosynthetic enzymes can be constructed by linking the genes or gene fragments encoding the enzymes to plant promoter sequences. Alternatively, chimeric genes designed to express antisense RNA for all or part 20 of the instant nucleic acid fragments can be constructed by linking the genes or gene fragment in reverse orientation to plant promoter sequences. Either the co-suppression or antisense chimeric genes could be introduced into plants via transformation wherein expression of the corresponding endogenous genes are reduced or eliminated.

25 The instant isoflavone biosynthetic enzymes (or portions of the enzymes) may be produced in heterologous host cells, particularly in the cells of microbial hosts, and can be used to prepare antibodies to the enzymes by methods well known to those skilled in the art. The antibodies are useful for detecting the enzymes *in situ* in cells or *in vitro* in cell extracts. Preferred heterologous host cells for production of the instant isoflavone biosynthetic enzymes are microbial hosts. Microbial expression systems and expression vectors 30 containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct chimeric genes for production of the instant isoflavone biosynthetic enzymes. These chimeric genes could then be introduced into appropriate microorganisms via transformation to provide high level expression of the enzymes. An example of a vector for high level expression of the instant 35 isoflavone biosynthetic enzymes in a bacterial host is provided (Example 5).

All or a portion of the nucleic acid fragments of the instant invention may also be used as probes for genetically and physically mapping the genes that they are a part of, and as markers for traits linked to those genes. Such information may be useful in plant breeding in

order to develop lines with desired phenotypes. For example, the instant nucleic acid fragments may be used as restriction fragment length polymorphism (RFLP) markers. Southern blots (Maniatis) of restriction-digested plant genomic DNA may be probed with the nucleic acid fragments of the instant invention. The resulting banding patterns may then be subjected to genetic analyses using computer programs such as MapMaker (Lander et al., (1987) *Genomics* 1:174-181) in order to construct a genetic map. In addition, the nucleic acid fragments of the instant invention may be used to probe Southern blots containing restriction endonuclease-treated genomic DNAs of a set of individuals representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is noted and used to calculate the position of the instant nucleic acid sequence in the genetic map previously obtained using this population (Botstein, D. et al., (1980) *Am. J. Hum. Genet.* 32:314-331).

For example, the instant nucleic acid fragments may be used as restriction fragment length polymorphism (RFLP) markers. Southern blots (Maniatis) of restriction-digested plant genomic DNA may be probed with the nucleic acid fragments of the instant invention. The resulting banding patterns may then be subjected to genetic analyses using computer programs such as MapMaker (Lander et al., (1987) *Genomics* 1:174-181) in order to construct a genetic map. In addition, the nucleic acid fragments of the instant invention may be used to probe Southern blots containing restriction endonuclease-treated genomic DNAs of a set of individuals representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is noted and used to calculate the position of the instant nucleic acid sequence in the genetic map previously obtained using this population (Botstein, D. et al., (1980) *Am. J. Hum. Genet.* 32:314-331).

The production and use of plant gene-derived probes for use in genetic mapping is described in R. Bernatzky, R. and Tanksley, S.D. (1986) *Plant Mol. Biol. Reporter* 4(1):37-41. Numerous publications describe genetic mapping of specific cDNA clones using the methodology outlined above or variations thereof. For example, F2 intercross populations, backcross populations, randomly mated populations, near isogenic lines, and other sets of individuals may be used for mapping. Such methodologies are well known to those skilled in the art.

Nucleic acid probes derived from the instant nucleic acid sequences may also be used for physical mapping (i.e., placement of sequences on physical maps; see Hoheisel, J. D., et al., In: *Nonmammalian Genomic Analysis: A Practical Guide*, Academic press 1996, pp. 319-346, and references cited therein).

In another embodiment, nucleic acid probes derived from the instant nucleic acid sequences may be used in direct fluorescence *in situ* hybridization (FISH) mapping (Trask, B. J. (1991) *Trends Genet.* 7:149-154). Although current methods of FISH mapping favor use of large clones (several to several hundred KB; see Laan, M. et al. (1995) *Genome*

Research 5:13-20), improvements in sensitivity may allow performance of FISH mapping using shorter probes.

A variety of nucleic acid amplification-based methods of genetic and physical mapping may be carried out using the instant nucleic acid sequences. Examples include 5 allele-specific amplification (Kazazian, H. H. (1989) *J. Lab. Clin. Med.* 114(2):95-96), polymorphism of PCR-amplified fragments (CAPS; Sheffield, V. C. et al. (1993) *Genomics* 16:325-332), allele-specific ligation (Landegren, U. et al. (1988) *Science* 241:1077-1080), nucleotide extension reactions (Sokolov, B. P. (1990) *Nucleic Acid Res.* 18:3671), Radiation Hybrid Mapping (Walter, M. A. et al. (1997) *Nature Genetics* 7:22-28) and Happy Mapping 10 (Dear, P. H. and Cook, P. R. (1989) *Nucleic Acid Res.* 17:6795-6807). For these methods, the sequence of a nucleic acid fragment is used to design and produce primer pairs for use in the amplification reaction or in primer extension reactions. The design of such primers is well known to those skilled in the art. In methods employing PCR-based genetic mapping, it may be necessary to identify DNA sequence differences between the parents of the 15 mapping cross in the region corresponding to the instant nucleic acid sequence. This, however, is generally not necessary for mapping methods.

Loss of function mutant phenotypes may be identified for the instant cDNA clone encoding chalcone isomerase either by targeted gene disruption protocols or by identifying 20 specific mutants for these genes contained in a maize population carrying mutations in all possible genes (Ballinger and Benzer, (1989) *Proc. Natl. Acad. Sci USA* 86:9402; Koes et al., (1995) *Proc. Natl. Acad. Sci USA* 92:8149; Bensen et al., (1995) *Plant Cell* 7:75). The latter approach may be accomplished in two ways. First, short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols in conjunction with a mutation tag sequence primer on DNAs prepared from a population of plants in which 25 Mutator transposons or some other mutation-causing DNA element has been introduced (see Bensen, *supra*). The amplification of a specific DNA fragment with these primers indicates the insertion of the mutation tag element in or near the genes encoding the plant chalcone isomerase. Alternatively, the instant nucleic acid fragments may be used as hybridization probes against PCR amplification products generated from the mutation 30 population using the mutation tag sequence primer in conjunction with an arbitrary genomic site primer, such as that for a restriction enzyme site-anchored synthetic adaptor. With either method, a plant containing a mutation in the chalcone isomerase gene can be identified and obtained. This mutant plant can then be used to determine or confirm the natural function of the plant gene product.

35

EXAMPLES

The present invention is further defined in the following Examples, in which all parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention,

are given by **5** of illustration only. From the above description and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

EXAMPLE 1

Composition of cDNA Libraries: Isolation and Sequencing of cDNA Clones

10 cDNA libraries representing mRNAs from various soybean tissues were prepared. The characteristics of the libraries are described below.

TABLE 2

cDNA Libraries from Soybean

Library	Tissue	Clone
se3	Soybean Embryo 13 Days After Flowering	se3.pk0034.g5
sre	Soybean Root, Elongation Zone	sre.pk0016.c8
ssm	Soybean Shoot Meristem	ssm.pk0013.e3

15 cDNA libraries were prepared in Uni-ZAP™ XR vectors according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA). Conversion of the Uni-ZAP™ XR libraries into plasmid libraries was accomplished according to the protocol provided by Stratagene. Upon conversion, cDNA inserts were contained in the plasmid vector pBluescript. cDNA inserts from randomly picked bacterial colonies containing recombinant pBluescript plasmids were amplified via polymerase chain reaction using primers specific for vector sequences flanking the inserted cDNA sequences or plasmid **20** DNA was prepared from cultured bacterial cells. Amplified insert DNAs or plasmid DNAs were sequenced in dye-primer sequencing reactions to generate partial cDNA sequences (expressed sequence tags or "ESTs"; see Adams, M. D. et al., (1991) *Science* 252:1651). The resulting ESTs were analyzed using a Perkin Elmer Model 377 fluorescent sequencer.

EXAMPLE 2

Identification and Characterization of cDNA Clones

25 ESTs encoding soybean isoflavone biosynthetic enzymes were identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul, S. F., et al., (1993) *J. Mol. Biol.* 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/) searches for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank **30** CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm provided by the National Center for Biotechnology Information **35** (NCBI). The DNA sequences were translated in all reading frames and compared for

similarity to all publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish, W. and States, D. J. (1993) *Nature Genetics* 3:266-272) provided by the NCBI. For convenience, the P-value (probability) of observing a match of a cDNA sequence to a sequence contained in the searched databases merely by chance as calculated by BLAST are reported herein as "pLog" values, which represent the negative of the logarithm of the reported P-value. Accordingly, the greater the pLog value, the greater the likelihood that the cDNA sequence and the BLAST "hit" represent homologous proteins.

5 The BLASTX search using the nucleotide sequence from clone ssm.pk0013.e3 revealed similarity of the protein encoded by the cDNA to *Pueraria lobata* chalcone 10 flavanone isomerase (DDJB Accession No. D63577; pLog = 71.37). The sequence of the entire cDNA insert in clone ssm.pk0013.e3 was determined and is set forth in SEQ ID NO:1; the deduced amino acid sequence of this cDNA is shown in SEQ ID NO:2. The entire cDNA insert in clone ssm.pk0013.e3 was reevaluated by BLAST, yielding an even higher pLog 15 value vs. the *Pueraria lobata* chalcone flavanone isomerase (D63577; pLog = 126.29). Sequence alignments and BLAST scores and probabilities indicate that the instant nucleic acid fragment encodes the entire soybean chalcone isomerase enzyme. This is the first 15 soybean EST identified for chalcone isomerase.

The BLASTX search using the nucleotide sequence from clone se3.pk0034.g5 revealed similarity of the protein encoded by the cDNA to *Lupinus albus* isoflavone 20 reductase-like protein (GenBank Accession No. U48590; pLog = 68.24). The sequence of the entire cDNA insert in clone se3.pk0034.g5 was determined and is set forth in SEQ ID NO:4; the deduced amino acid sequence of this cDNA is shown in SEQ ID NO:5. The entire cDNA insert in clone se3.pk0034.g5 was reevaluated by BLAST, yielding an even 25 higher pLog value vs. an isoflavone reductase homolog from *Lupinus albus* (SWISS-PROT Accession No. P52581; pLog = 171.54). Sequence alignments and BLAST scores and probabilities indicate that the instant nucleic acid fragment encodes the entire soybean isoflavone reductase enzyme. This is the first soybean EST identified for isoflavone reductase.

30 The BLASTX search using the nucleotide sequence from clone sre.pk0016.c8 revealed similarity of the protein encoded by the cDNA to *Medicago sativa* vestitone reductase (GenBank Accession No. U28213; pLog = 52.57). The sequence of the entire cDNA insert in clone sre.pk0016.c8 was determined and is set forth in SEQ ID NO:7; the deduced amino acid sequence of this cDNA is shown in SEQ ID NO:8. The entire cDNA insert in clone sre.pk0016.c8 was reevaluated by BLAST, yielding an even higher pLog value vs. the 35 *Medicago sativa* vestitone reductase (U28213; pLog = 170.39). Sequence alignments and BLAST scores and probabilities indicate that the instant nucleic acid fragment encodes the entire soybean vestitone reductase enzyme. This is the first soybean EST identified for vestitone reductase.

EXAMPLE 3Expression of Chimeric Genes in Monocot Cells

A chimeric gene comprising a cDNA encoding an isoflavone biosynthetic enzyme, for example chalcone isomerase, in sense orientation with respect to the maize 27 kD zein promoter that is located 5' to the cDNA fragment, and the 10 kD zein 3' end that is located 3' to the cDNA fragment, can be constructed. The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites (NcoI or SmaI) can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the digested vector pML103 as described below. Amplification is then performed in a standard PCR. The amplified DNA is then digested with restriction enzymes NcoI and SmaI and fractionated on an agarose gel. The appropriate band can be isolated from the gel and combined with a 4.9 kb NcoI-SmaI fragment of the plasmid pML103. Plasmid pML103 has been deposited under the terms of the Budapest Treaty at ATCC (American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209), and bears accession number ATCC 97366. The DNA segment from pML103 contains a 1.05 kb Sall-NcoI promoter fragment of the maize 27 kD zein gene and a 0.96 kb SmaI-Sall fragment from the 3' end of the maize 10 kD zein gene in the vector pGem9Zf(+) (Promega). Vector and insert DNA can be ligated at 15°C overnight, essentially as described (Maniatis). The ligated DNA may then be used to transform *E. coli* XL1-Blue (Epicurian Coli XL-1 Blue™, Stratagene). Bacterial transformants can be screened by restriction enzyme digestion of plasmid DNA and limited nucleotide sequence analysis using the dideoxy chain termination method (Sequenase™ DNA Sequencing Kit; U.S. Biochemical). The resulting plasmid construct would comprise a chimeric gene encoding, in the 5' to 3' direction, the maize 27 kD zein promoter, a cDNA fragment encoding a soybean isoflavone biosynthetic enzyme, and the 10 kD zein 3' region.

The chimeric gene described above can then be introduced into corn cells by the following procedure. Immature corn embryos can be dissected from developing caryopses derived from crosses of the inbred corn lines H99 and LH132. The embryos are isolated 10 to 11 days after pollination when they are 1.0 to 1.5 mm long. The embryos are then placed with the axis-side facing down and in contact with agarose-solidified N6 medium (Chu et al., (1975) *Sci. Sin. Peking* 18:659-668). The embryos are kept in the dark at 27°C. Friable embryogenic callus consisting of undifferentiated masses of cells with somatic proembryoids and embryoids borne on suspensor structures proliferates from the scutellum of these immature embryos. The embryogenic callus isolated from the primary explant can be cultured on N6 medium and sub-cultured on this medium every 2 to 3 weeks.

The plasmid, p35S/Ac (obtained from Dr. Peter Eckes, Hoechst Ag, Frankfurt, Germany) may be used in transformation experiments in order to provide for a selectable

marker. This plasmid contains the *Pat* gene (see European Patent Publication 0 242 236) which encodes phosphinothricin acetyl transferase (PAT). The enzyme PAT confers resistance to herbicidal glutamine synthetase inhibitors such as phosphinothricin. The *pat* gene in p35S/Ac is under the control of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*.

5 The particle bombardment method (Klein et al., (1987) *Nature* 327:70-73) may be used to transfer genes to the callus culture cells. According to this method, gold particles (1 μ m in diameter) are coated with DNA using the following technique. Ten μ g of plasmid 10 DNAs are added to 50 μ L of a suspension of gold particles (60 mg per mL). Calcium chloride (50 μ L of a 2.5 M solution) and spermidine free base (20 μ L of a 1.0 M solution) are added to the particles. The suspension is vortexed during the addition of these solutions. After 10 minutes, the tubes are briefly centrifuged (5 sec at 15,000 rpm) and the supernatant 15 removed. The particles are resuspended in 200 μ L of absolute ethanol, centrifuged again and the supernatant removed. The ethanol rinse is performed again and the particles resuspended in a final volume of 30 μ L of ethanol. An aliquot (5 μ L) of the DNA-coated gold particles can be placed in the center of a KaptonTM flying disc (Bio-Rad Labs). The particles are then accelerated into the corn tissue with a BiolisticTM PDS-1000/He (Bio-Rad 20 Instruments, Hercules CA), using a helium pressure of 1000 psi, a gap distance of 0.5 cm and a flying distance of 1.0 cm.

For bombardment, the embryogenic tissue is placed on filter paper over agarose-solidified N6 medium. The tissue is arranged as a thin lawn and covered a circular area of 25 about 5 cm in diameter. The petri dish containing the tissue can be placed in the chamber of the PDS-1000/He approximately 8 cm from the stopping screen. The air in the chamber is then evacuated to a vacuum of 28 inches of Hg. The macrocarrier is accelerated with a helium shock wave using a rupture membrane that bursts when the He pressure in the shock tube reaches 1000 psi.

30 Seven days after bombardment the tissue can be transferred to N6 medium that contains glufosinate (2 mg per liter) and lacks casein or proline. The tissue continues to grow slowly on this medium. After an additional 2 weeks the tissue can be transferred to fresh N6 medium containing glufosinate. After 6 weeks, areas of about 1 cm in diameter of actively growing callus can be identified on some of the plates containing the glufosinate-supplemented medium. These calli may continue to grow when sub-cultured on the selective medium.

35 Plants can be regenerated from the transgenic callus by first transferring clusters of tissue to N6 medium supplemented with 0.2 mg per liter of 2,4-D. After two weeks the tissue can be transferred to regeneration medium (Frömm et al., (1990) *Bio/Technology* 8:833-839).

EXAMPLE 4Expression of Chimeric Genes in Dicot Cells

A seed-specific expression cassette composed of the promoter and transcription terminator from the gene encoding the β subunit of the seed storage protein phaseolin from the bean *Phaseolus vulgaris* (Doyle et al. (1986) *J. Biol. Chem.* 261:9228-9238) can be used for expression of the instant soybean isoflavone biosynthetic enzymes in transformed soybean. The phaseolin cassette includes about 500 nucleotides upstream (5') from the translation initiation codon and about 1650 nucleotides downstream (3') from the translation stop codon of phaseolin. Between the 5' and 3' regions are the unique restriction endonuclease sites Nco I (which includes the ATG translation initiation codon), Sma I, Kpn I and Xba I. The entire cassette is flanked by Hind III sites.

A cDNA fragment encoding any of the instant soybean isoflavone biosynthetic enzymes may be generated by polymerase chain reaction (PCR) of the appropriate cDNA clones using appropriate oligonucleotide primers. Cloning sites can be incorporated into the oligonucleotides to provide proper orientation of the amplified DNA fragment when inserted into the expression vector. Amplification is then performed in a standard PCR, and the isolated fragment is inserted into a pUC18 vector carrying the seed expression cassette.

Soybean embryos may then be transformed with the expression vector comprising sequences encoding a soybean isoflavone biosynthetic enzyme. To induce somatic embryos, cotyledons, 3-5 mm in length dissected from surface sterilized, immature seeds of the soybean cultivar A2872, can be cultured in the light or dark at 26°C on an appropriate agar medium for 6-10 weeks. Somatic embryos which produce secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos which multiplied as early, globular staged embryos, the suspensions are maintained as described below.

Soybean embryogenic suspension cultures can be maintained in 35 mL liquid media on a rotary shaker, 150 rpm, at 26°C with fluorescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 mL of liquid medium.

Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Kline et al. (1987) *Nature* (London) 327:70, U.S. Patent No. 4,945,050). A Du Pont Biolistic™ PDS1000/HE instrument (helium retrofit) can be used for these transformations.

A selectable marker gene which can be used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from *E. coli*; Gritz et al. (1983) *Gene* 25:179-188) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*. The seed expression

cassette comprising the phaseolin 5' region, the fragment encoding the biosynthetic enzyme and the phaseolin 3' region can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.

To 50 μ L of a 60 mg/mL 1 μ m gold particle suspension is added (in order): 5 μ L 5 DNA (1 μ g/ μ L), 20 μ L spermidine (0.1 M), and 50 μ L CaCl₂ (2.5 M). The particle preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400 μ L 70% ethanol and resuspended in 40 μ L of anhydrous ethanol. The DNA/particle suspension can be sonicated three times for one second each. Five μ L of the DNA-coated gold particles are 10 then loaded on each macro carrier disk.

Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally 15 bombarded. Membrane rupture pressure is set at 1100 psi and the chamber is evacuated to a vacuum of 28 inches mercury. The tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.

Five to seven days post bombardment, the liquid media may be exchanged with fresh 20 media, and eleven to twelve days post bombardment with fresh media containing 50 mg/mL hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post bombardment, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These 25 suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.

EXAMPLE 5

Expression of Chimeric Genes in Microbial Cells

The nucleic acid fragments encoding the instant soybean isoflavone biosynthetic 30 enzymes can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and Hind III sites was inserted at the BamH I site 35 of pET-3a. This created pET-3aM with additional unique cloning sites for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region, 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the enzyme. This fragment may then be purified on a 1% NuSieve GTG™ low melting agarose gel (FMC). Buffer and agarose contain 10 µg/ml ethidium bromide for visualization of the DNA fragment. The fragment can then be purified from the agarose gel by digestion with GELase™ (Epicentre Technologies) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 µL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase (New England Biolabs, Beverly, MA). The fragment containing the ligated adapters can be purified from the excess adapters using low melting agarose as described above. The vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5 electrocompetent cells (GIBCO BRL). Transformants can be selected on agar plates containing LB media and 100 µg/mL ampicillin. Transformants containing the gene encoding the enzyme are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.

For high level expression, a plasmid clone with the cDNA insert in the correct orientation relative to the T7 promoter can be transformed into *E. coli* strain BL21(DE3) (Studier et al. (1986) *J. Mol. Biol.* 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25°C. At an optical density at 600 nm of approximately 1, IPTG (isopropylthio-β-galactoside, the inducer) can be added to a final concentration of 0.4 mM and incubation can be continued for 3 h at 25°. Cells are then harvested by centrifugation and re-suspended in 50 µL of 50 mM Tris-HCl at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe sonicator. The mixture is centrifuged and the protein concentration of the supernatant determined. One µg of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight.


30

CLAIMS

What is claimed is:

1. An isolated nucleic acid fragment encoding a chalcone isomerase comprising a member selected from the group consisting of:
 - 5 (a) an isolated nucleic acid fragment encoding all or a substantial portion of the amino acid sequence set forth in SEQ ID NO:2;
 - (b) an isolated nucleic acid fragment that is substantially similar to an isolated nucleic acid fragment encoding all or a substantial portion of the amino acid sequence set forth in SEQ ID NO:2; and
 - 10 (c) an isolated nucleic acid fragment that is complementary to (a) or (b).
2. The isolated nucleic acid fragment of Claim 1 wherein the nucleotide sequence of the fragment is set forth in SEQ ID NO:1.
3. A chimeric gene comprising the nucleic acid fragment of Claim 1 operably linked to suitable regulatory sequences.
- 15 4. A transformed host cell comprising the chimeric gene of Claim 3.
5. An isolated nucleic acid fragment encoding an isoflavone reductase comprising a member selected from the group consisting of:
 - 20 (a) an isolated nucleic acid fragment encoding all or a substantial portion of the amino acid sequence set forth in SEQ ID NO:5;
 - (b) an isolated nucleic acid fragment that is substantially similar to an isolated nucleic acid fragment encoding all or a substantial portion of the amino acid sequence set forth in SEQ ID NO:5; and
 - (c) an isolated nucleic acid fragment that is complementary to (a) or (b).
6. The isolated nucleic acid fragment of Claim 1 wherein the nucleotide sequence 25 of the fragment is set forth in SEQ ID NO:4.
7. A chimeric gene comprising the nucleic acid fragment of Claim 5 operably linked to suitable regulatory sequences.
8. A transformed host cell comprising the chimeric gene of Claim 7.
9. An isolated nucleic acid fragment encoding a vestitone reductase comprising a 30 member selected from the group consisting of:
 - (a) an isolated nucleic acid fragment encoding all or a substantial portion of the amino acid sequence set forth in SEQ ID NO:8;
 - (b) an isolated nucleic acid fragment that is substantially similar to an isolated nucleic acid fragment encoding all or a substantial portion of the amino acid sequence set forth in SEQ ID NO:8; and
 - (c) an isolated nucleic acid fragment that is complementary to (a) or (b).
- 35 10. The isolated nucleic acid fragment of Claim 9 wherein the nucleotide sequence of the fragment is set forth in SEQ ID NO:7.

11. A chimeric gene comprising the nucleic acid fragment of Claim 9 operably linked to suitable regulatory sequences.
12. A transformed host cell comprising the chimeric gene of Claim 11.
13. A method of altering the level of expression of a plant isoflavone biosynthetic enzyme in a host cell comprising:
 - (a) transforming a host cell with the chimeric gene of any of Claims 3, 7 or 11; and
 - (b) growing the transformed host cell produced in step (a) under conditions that are suitable for expression of the chimeric gene
- 10 wherein expression of the chimeric gene results in production of altered levels of a plant isoflavone biosynthetic enzyme in the transformed host cell.
14. A method of obtaining a nucleic acid fragment encoding all or a substantial portion of the amino acid sequence encoding a plant isoflavone biosynthetic enzyme comprising:
 - (a) probing a cDNA or genomic library with the nucleic acid fragment of any of Claims 1, 5 and 9;
 - (b) identifying a DNA clone that hybridizes with the nucleic acid fragment of any of Claims 1, 5 and 9;
 - (c) isolating the DNA clone identified in step (b); and
 - (d) sequencing the cDNA or genomic fragment that comprises the clone isolated in step (c)
- 20 wherein the sequenced nucleic acid fragment encodes all or a substantial portion of the amino acid sequence encoding a plant isoflavone biosynthetic enzyme.
15. A method of obtaining a nucleic acid fragment encoding all or a substantial portion of an amino acid sequence encoding a plant isoflavone biosynthetic enzyme comprising:
 - (a) synthesizing an oligonucleotide primer corresponding to a portion of the sequence set forth in any of SEQ ID NOs:1, 4, or 7; and
 - (b) amplifying a cDNA insert present in a cloning vector using the oligonucleotide primer of step (a) and a primer representing sequences of the cloning vector
- 25 wherein the amplified nucleic acid fragment encodes all or a substantial portion of an amino acid sequence encoding a plant isoflavone biosynthetic enzyme.
16. The product of the method of Claim 14.
- 30 17. The product of the method of Claim 15.



2/4

FIG. 2

1	MAAAAVATISAVQVEFFPAVVTSPASGRTYFLGGAGE	D63577
1	M-----ATISAVQVEFFPAVVTSPASGKTYFLGGAGE	ssm.pk0013.e3
41	RGLTIEGKFEIKFTGIGVYLEDKA	
35	VSSLAAKWKGKPSSEELV	D63577
	ssm.pk0013.e3	
50		
60		
70		
80		
81	ETLDFYRDIISGPFEKLI	
75	RDIISGPFEKLI	D63577
	RGSKILPLSGVEYSKKVME	CV
	ssm.pk0013.e3	
90		
100		
110		
120		
130		
140		
150		
160		
121	AHMKSVGTYGDAEAAAIEKFAEA	
115	AFKNVNQPGATVFYRQS	D63577
	ssm.pk0013.e3	
170		
180		
190		
200		
161	PDGVLGILSFSEDVVTIPDNE	
155	AVIENKAVSAAVLETMIGEH	D63577
	ssm.pk0013.e3	
210		
220		
201	AVSPDLKRSLASRLPAVLSHGIVV.	D63577
195	AVSPDLKRSLASRLPAVLSHGIVV.	ssm.pk0013.e3

3/4

FIG. 3

1	M G K S K V L V V G G T G Y V G R R I V K A S L E H G H E T F I L Q R P E I G L D I E K L Q I L L S	50
1	M G K S K V L V V G G T G Y I G R R I V R A S S L A L G H E T Y V V Q R P E L S L Q I E K L Q R L L S	P52581 se3.pk0034.95
51	F K K Q G A I L V E A S F S D H K S L V D A V K L V D V V I C T M S G V H F R S H N L L T Q L K L V	100
51	F K K Q G A H L I E A S F N D H K S L V D A V K Q V D V V I S A I S G V H I R S H S I T L Q L K L V	P52581 se3.pk0034.95
101	E A I K D A G N I K R F L P S E F G M D P A L M G H A L E P G R V T F D E K M T V R K A I E E A N I	150
101	E A I K E A G N V K R F L P S E F G I D P A R M G H A L E P G R V T F E D K M A V R K P I E E A N I	P52581 se3.pk0034.95
151	P F T Y I S A N C F A G Y F A G N L S Q M K T L L P P P R D K V L L Y G D G N V K P V Y M D E D D V A	200
151	P F T Y I S A N L F A G Y F A G S L S Q M G S F V P P R D K V H L F G D G T L K A I F L D E D D V A	P52581 se3.pk0034.95
201	T Y T I K T I D D P R T L N K T V Y L R P P E N I L T H K E L I E K W E E L I G K O L E K N S I S E	250
201	T Y T I K A I D D P R T L N K T L Y L R P P E N I I F Q A E L I G I W E K L I G K E L K T Y I P P	P52581 se3.pk0034.95
251	K D F L S T I K G L D F A S Q V G V G H F Y H I F Y E G C L T N F E I G E N G E E A S E L Y P E V N	300
251	E G F L T T I K G L D Y K L Q V G I G H E Y H I F Y E G C L A N F E I G E E E A S K L Y P E V N	P52581 se3.pk0034.95
301	Y T R M D Q Y L K V Y - V	
301	Y T R M D E Y L K I Y V	P52581 se3.pk0034.95

FIG. 4

4/4

10	20	30	40	50
MAEGKGRVCVTTGGTGFGLSWIJKSLLNGYSVNTTIRADPERKRKDVSFLT				U28213
1 NGEKGKRICVTTGGTGFGLSWIJKSLLHEGYAVNTTIRSDPGRKRDVSFLT				sre.pk0016.c8
60	70	80	90	100
SQLPGASEKLHFVNADLSNPDSFAAAIEGCVGIFHTASPIDFAVSEPEEEIV				U28213
SQLPGASEKLKIFNADLSDPESFGPAVEGCCVGIFHTATPIDFAVNPEEEVV				sre.pk0016.c8
110	120	130	140	150
101TKRTVDGALGILKACVNSKTVKREFIYTSGSAVSFNG-KDKDVLIDESDW				S U28213
101TKRAIDGALGILKAGLKAKTVKRVVYTSASSTVSSLEEKDVFVDESVWS				sre.pk0016.c8
160	170	180	190	200
150DV DLLRSVKPFGWNYAVSKTLAEKAVLEFGEQNGIDVVTLILPFLIVGRFV				U28213
151DV DLLRSVKPFSWSYAVSKVLSSEKAVLEFGEQNGLEVTTLVLPFVVGRFV				sre.pk0016.c8
210	220	230	240	250
200CPKLPDSIEKALVLVLGKKEQIGVTREFHMVHVDVVARAHIIYLLENSVP				G U28213
201CPKLPDSVERALLVLVLGKKEEIGVTRYHMMVHVDVVARAHIFILLEHPNPKG				sre.pk0016.c8
260	270	280	290	300
250RYNCSPPFIVPIEEEMSQLLSAKYPEYQILTVDELKIEIKGARLPDLNTKKLV				U28213
251RYNCSPPFIVPIEEIAEIIISAKYPEYQIPALEEVKEIKGAKLPHILTSQKLV				sre.pk0016.c8
310	320			
300DAGEDEFKTYTIEDMFDDAIQCCKEKGY-L				U28213
301DAGFEFKYSVEDIFTDAIECCKEKGYL				sre.pk0016.c8

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:
(A) ADDRESSEE: E. I. DU PONT DE NEMOURS AND COMPANY
(B) STREET: 1007 MARKET STREET
(C) CITY: WILMINGTON
(D) STATE: DELAWARE
(E) COUNTRY: UNITED STATES OF AMERICA
(F) ZIP: 19898
(G) TELEPHONE: 302-992-4926
(H) TELEFAX: 302-773-0164
(I) TELEX: 6717325

(ii) TITLE OF INVENTION: ISOFLAVONE BIOSYNTHETIC ENZYMES

(iii) NUMBER OF SEQUENCES: 9

(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: DISKETTE, 3.50 INCH
(B) COMPUTER: IBM PC COMPATIBLE
(C) OPERATING SYSTEM: MICROSOFT WINDOWS 95
(D) SOFTWARE: MICROSOFT WORD VERSION 7.0A

(v) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/931,668
(B) FILING DATE: SEPTEMBER 17, 1997

(vii) ATTORNEY/AGENT INFORMATION:
(A) NAME: MAJARIAN, WILLIAM R.
(B) REGISTRATION NUMBER: 41,173
(C) REFERENCE/DOCKET NUMBER: BB-1098-B

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 846 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS
 (B) LOCATION: 40..693

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

AATTCGGCAC GAGGTTAAAT AGAAAAGAGG AGTTTGAGA ATG GCA ACG ATC AGC	54
Met Ala Thr Ile Ser	
1 5	
GCG GTT CAG GTG GAG TTC CTG GAG TTT CCA GCG GTG GTT ACT TCA CCA	102
Ala Val Gln Val Glu Phe Leu Glu Phe Pro Ala Val Val Thr Ser Pro	
10 15 20	
GCC TCC GGC AAG ACC TAT TTC CTC GGC GGC GCA GGG GAG AGA GGA TTG	150
Ala Ser Gly Lys Thr Tyr Phe Leu Gly Gly Ala Gly Glu Arg Gly Leu	
25 30 35	
ACG ATT GAG GGG AAG TTC ATA AAG TTC ACA GGC ATA GGA GTA TAC TTG	198
Thr Ile Glu Gly Lys Phe Ile Lys Phe Thr Gly Ile Gly Val Tyr Leu	
40 45 50	
GAG GAT AAG GCG GTG CCA TCA CTC GCC GCT AAG TGG AAG GGT AAA ACT	246
Glu Asp Lys Ala Val Pro Ser Leu Ala Ala Lys Trp Lys Gly Lys Thr	
55 60 65	
TCA GAG GAG TTA GTT CAC ACC CTC CAC TTC TAC AGG GAT ATC ATT TCA	294
Ser Glu Glu Leu Val His Thr Leu His Phe Tyr Arg Asp Ile Ile Ser	
70 75 80 85	
GGG CCG TTT GAA AAG CTA ATT AGA GGG TCG AAG ATT CTG CCA TTG GCT	342
Gly Pro Phe Glu Lys Leu Ile Arg Gly Ser Lys Ile Leu Pro Leu Ala	
90 95 100	
GGC GCT GAA TAC TCA AAG AAG GTG ATG GAA AAC TGC GTG GCA CAC ATG	390
Gly Ala Glu Tyr Ser Lys Lys Val Met Glu Asn Cys Val Ala His Met	
105 110 115	
AAG TCT GTT GGG ACT TAC GGT GAT GCT GAA GCC GCA GCC ATT GAA AAG	438
Lys Ser Val Gly Thr Tyr Gly Asp Ala Glu Ala Ala Ala Ile Glu Lys	
120 125 130	
TTT GCT GAA GCC TTC AAG AAT GTG AAT TTT GCA CCT GGT GCC TCT GTT	486
Phe Ala Glu Ala Phe Lys Asn Val Asn Phe Ala Pro Gly Ala Ser Val	
135 140 145	
TTC TAC AGA CAA TCA CCT GAT GGA ATC TTG GGG CTT AGT TTC TCT GAA	534
Phe Tyr Arg Gln Ser Pro Asp Gly Ile Leu Gly Leu Ser Phe Ser Glu	
150 155 160 165	
GAT GCA ACA ATA CCA GAA AAG GAG GCT GCA GTG ATA GAG AAC AAG GCT	582
Asp Ala Thr Ile Pro Glu Lys Glu Ala Ala Val Ile Glu Asn Lys Ala	
170 175 180	

GTA TCA GCG	GTC TTG GAG ACC ATG ATT GGT GAA	GCT GTT TCC	630
Val Ser Ala Ala Val Leu Glu Thr Met Ile Gly Glu His Ala Val Ser	185 190 195		
CCT GAC TTA AAA CGC AGT TTG GCT TCT CGA TTG CCT GCG GTA TTG AGC	678		
Pro Asp Leu Lys Arg Ser Leu Ala Ser Arg Leu Pro Ala Val Leu Ser	200 205 210		
CAC GGC ATT ATA GTC TGAGAAATGA GAAGGATCAA CTTTACCTTT TTCAAATATT	733		
His Gly Ile Ile Val	215		
CTTGTTCCTT CTCCTTCTTT CTTGTCGCTT GTCATGTATT TCTACTGTTT TATTAAATAA	793		
TAAAAATTGAG TTCTGTTAGA GTTGGTGAAA AAAAAAAA AAAAAAAACT CGA	846		

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 218 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Ala Thr Ile Ser Ala Val Gln Val Glu Phe Leu Glu Phe Pro Ala	1 5 10 15
Val Val Thr Ser Pro Ala Ser Gly Lys Thr Tyr Phe Leu Gly Gly Ala	20 25 30
Gly Glu Arg Gly Leu Thr Ile Glu Gly Lys Phe Ile Lys Phe Thr Gly	35 40 45
Ile Gly Val Tyr Leu Glu Asp Lys Ala Val Pro Ser Leu Ala Ala Lys	50 55 60
Trp Lys Gly Lys Thr Ser Glu Glu Leu Val His Thr Leu His Phe Tyr	65 70 75 80
Arg Asp Ile Ile Ser Gly Pro Phe Glu Lys Leu Ile Arg Gly Ser Lys	85 90 95
Ile Leu Pro Leu Ala Gly Ala Glu Tyr Ser Lys Lys Val Met Glu Asn	100 105 110
Cys Val Ala His Met Lys Ser Val Gly Thr Tyr Gly Asp Ala Glu Ala	115 120 125
Ala Ala Ile Glu Lys Phe Ala Glu Ala Phe Lys Asn Val Asn Phe Ala	130 135 140
Pro Gly Ala Ser Val Phe Tyr Arg Gln Ser Pro Asp Gly Ile Leu Gly	145 150 155 160
Leu Ser Phe Ser Glu Asp Ala Thr Ile Pro Glu Lys Glu Ala Ala Val	165 170 175
Ile Glu Asn Lys Ala Val Ser Ala Ala Val Leu Glu Thr Met Ile Gly	180 185 190
Glu His Ala Val Ser Pro Asp Leu Lys Arg Ser Leu Ala Ser Arg Leu	195 200 205

Pro Ala Val **u** Ser His Gly Ile Ile Val
 210 215

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 224 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Met Ala Ala Ala Ala Ala Val Ala Thr Ile Ser Ala Val Gln Val Glu
 1 5 10 15

Phe Leu Glu Phe Pro Ala Val Val Thr Ser Pro Ala Ser Gly Arg Thr
 20 25 30

Tyr Phe Leu Gly Gly Ala Gly Glu Arg Gly Leu Thr Ile Glu Gly Lys
 35 40 45

Phe Ile Lys Phe Thr Gly Ile Gly Val Tyr Leu Glu Asp Lys Ala Val
 50 55 60

Ser Ser Leu Ala Ala Lys Trp Lys Gly Lys Pro Ser Glu Glu Leu Val
 65 70 75 80

Glu Thr Leu Asp Phe Tyr Arg Asp Ile Ile Ser Gly Pro Phe Glu Lys
 85 90 95

Leu Ile Arg Gly Ser Lys Ile Leu Pro Leu Ser Gly Val Glu Tyr Ser
 100 105 110

Lys Lys Val Met Glu Asn Cys Val Ala His Met Lys Ser Val Gly Thr
 115 120 125

Tyr Gly Asp Ala Glu Ala Ala Ile Glu Lys Phe Ala Glu Ala Phe
 130 135 140

Lys Asn Val Asn Phe Gln Pro Gly Ala Thr Val Phe Tyr Arg Gln Ser
 145 150 155 160

Pro Asp Gly Val Leu Gly Leu Ser Phe Ser Glu Asp Val Thr Ile Pro
 165 170 175

Asp Asn Glu Ala Ala Val Ile Glu Asn Lys Ala Val Ser Ala Ala Val
 180 185 190

Leu Glu Thr Met Ile Gly Glu His Ala Val Ser Pro Asp Leu Lys Arg
 195 200 205

Ser Leu Ala Ser Arg Leu Pro Ala Val Leu Ser His Gly Ile Ile Val
 210 215 220

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1223 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS
 (B) LOCATION: 55..1223

(ix) FEATURE:

(A) NAME/KEY: CDS
 (B) LOCATION: 55..990

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

AATTCGGCAC	GAGGAAGAAC	CAACAAGAGG	GGTATTGAGA	TTGAGATTCA	AGTA	ATG	57
						Met	
						1	
GGG	AAG	AGC	AAG	GTT	CTT	GTG	105
Gly	Lys	Ser	Lys	Val	Leu	Val	
5	10						15
Gly	Gly	Gly	Gly	Thr	Gly	Tyr	
15							
AGG	ATA	GTG	AGG	GCA	AGC	CTG	153
Arg	Ile	Val	Arg	Ala	Ser	Leu	
20	25						30
Leu	Gly	His	Glu	Thr	Tyr	Tyr	
CAG	AGG	CCA	GAG	TTG	AGC	CTC	201
Gln	Arg	Pro	Glu	Leu	Ser	Leu	
35	40						45
Ile	Glu	Ile	Gly	Lys	Lys	Gly	
TCC	TTC	AAG	AAG	CAA	GGT	GCT	249
Ser	Phe	Lys	Lys	Gln	Gly	Ala	
50	55						65
His	Ile	Leu	Asp	Ala	Val	Lys	
	70					75	
Asp	Ala	Val	Asp	Val	Asp	Val	
CAC	AAG	AGC	CTT	GTT	GAT	GCT	297
His	Lys	Ser	Leu	Val	Asp	Ala	
75	80						
GCC	ATC	TCT	GGT	GTT	CAC	ATC	345
Ala	Ile	Ser	Gly	Val	His	Ile	
85	90						95
Arg	Ile	Arg	Ser	His	Ser	Ile	
AAA	CTT	GTT	GAG	GCC	ATC	AAA	393
Lys	Leu	Val	Glu	Ala	Ile	Lys	
100	105						110
Gly	Gly	Gly	Asn	Val	Gly	Arg	
CCT	TCT	GAA	TTT	GGC	CTA	GAC	441
Pro	Ser	Glu	Phe	Gly	Leu	Asp	
115	120						125
Arg	Pro	Ala	Arg	Met	Gly	His	
CCA	GGA	AGG	GTA	ACA	TTT	GAA	489
Pro	Gly	Arg	Val	Thr	Phe	Glu	
130	135						145
Asp	Glu	Lys	Met	Ala	Val	Arg	
GAG	GAA	GCT	AAT	ATC	CCT	ACT	537
Glu	Glu	Ala	Asn	Ile	Pro	Phe	
150	155						160
Thr	Thr	Ile	Ser	Ala	Asn	Leu	
GGA	TAC	TTT	GCT	GGC	AGC	CTC	585
Gly	Tyr	Phe	Ala	Gly	Ser	Leu	
165	170						175
Asp	Asp	Asp	His	Leu	Phe	Gly	
180	185						190
Arg	Arg	Arg	Leu	Phe	Gly	Asp	
CTG	GAT	GAA	GAT	GAT	GTT	GCA	681
Leu	Asp	Glu	Asp	Asp	Val	ACA	
195	200						205
Asp	Asp	Asp	Ala	Thr	Tyr	Ile	

CCA CGA ACC CTT AAC AAA ACA TTG TAC CTA AGG CCT CCA GAA AAT ATT Pro Arg Thr Leu Asn Lys Thr Leu Tyr Leu Arg Pro Pro Glu Asn Ile 210 215 220 225	729
ATC TTT CAA GCA GAG CTT ATT GGA ATT TGG GAG AAA CTT ATT GGA AAG Ile Phe Gln Ala Glu Leu Ile Gly Ile Trp Glu Lys Leu Ile Gly Lys 230 235 240	777
GAA CTA GAG AAG ACA TAC ATA CCT CCA GAA GGC TTT CTT ACA ACA CTG Glu Leu Glu Lys Thr Tyr Ile Pro Pro Glu Gly Phe Leu Thr Thr Leu 245 250 255	825
AAA GGG TTG GAT TAT AAA CTT CAA GTA GGG ATT GGA CAC TTT TAT CAT Lys Gly Leu Asp Tyr Lys Leu Gln Val Gly Ile Gly His Phe Tyr His 260 265 270	873
ATA TTC TAC GAG GGA TGT TTA GCA AAT TTT GAA ATT GGA GAG GAA GGA Ile Phe Tyr Glu Gly Cys Leu Ala Asn Phe Glu Ile Gly Glu Glu Gly 275 280 285	921
GAA GAA GCA TCC AAG CTT TAC CCT GAA GTG AAT TAC ACA CGC ATG GAC Glu Glu Ala Ser Lys Leu Tyr Pro Glu Val Asn Tyr Thr Arg Met Asp 290 295 300 305	969
GAG TAC CTA AAA ATT TAT GTG TAAAAGGAAC TCATTCACTA GGAGTTCACT Glu Tyr Leu Lys Ile Tyr Val 310	1020
GATTCAAACA GGAACACGGT TTTTAGCTAC AATAACCTTA ATTTAAGGAG ATGATTTGT GCTTATAATT CGATGGGGAA ACTGGATTTT TCGGATCTTG AAATGTGAAC GAGTTTAACT TTATCATTAA TTTAAGCTCT GTTGTTTA AAAAAAAA AAAAAAAA AAAAAAAA AAAAAAA AAAAAAAACT CGA	1080 1140 1200 1223

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 312 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Met Gly Lys Ser Lys Val Leu Val Val Gly Gly Thr Gly Tyr Ile Gly 1 5 10 15
Arg Arg Ile Val Arg Ala Ser Leu Ala Leu Gly His Glu Thr Tyr Val 20 25 30
Val Gln Arg Pro Glu Leu Ser Leu Gln Ile Glu Lys Leu Gln Arg Leu 35 40 45
Leu Ser Phe Lys Lys Gln Gly Ala His Leu Ile Glu Ala Ser Phe Asn 50 55 60
Asp His Lys Ser Leu Val Asp Ala Val Lys Gln Val Asp Val Val Ile 65 70 75 80
Ser Ala Ile Ser Gly Val His Ile Arg Ser His Ser Ile Thr Leu Gln 85 90 95

Leu Lys Leu Val Glu Ala Ile Lys Glu Ala Gly Asn Val Lys Arg Phe
 100 105 110

Leu Pro Ser Glu Phe Gly Leu Asp Pro Ala Arg Met Gly His Ala Leu
 115 120 125

Glu Pro Gly Arg Val Thr Phe Glu Asp Lys Met Ala Val Arg Lys Pro
 130 135 140

Ile Glu Glu Ala Asn Ile Pro Phe Thr Tyr Ile Ser Ala Asn Leu Phe
 145 150 155 160

Ala Gly Tyr Phe Ala Gly Ser Leu Ser Gln Met Gly Ser Phe Val Pro
 165 170 175

Pro Arg Asp Lys Val His Leu Phe Gly Asp Gly Thr Leu Lys Ala Ile
 180 185 190

Phe Leu Asp Glu Asp Asp Val Ala Thr Tyr Thr Ile Lys Ala Ile Asp
 195 200 205

Asp Pro Arg Thr Leu Asn Lys Thr Leu Tyr Leu Arg Pro Pro Glu Asn
 210 215 220

Ile Ile Phe Gln Ala Glu Leu Ile Gly Ile Trp Glu Lys Leu Ile Gly
 225 230 235 240

Lys Glu Leu Glu Lys Thr Tyr Ile Pro Pro Glu Gly Phe Leu Thr Thr
 245 250 255

Leu Lys Gly Leu Asp Tyr Lys Leu Gln Val Gly Ile Gly His Phe Tyr
 260 265 270

His Ile Phe Tyr Glu Gly Cys Leu Ala Asn Phe Glu Ile Gly Glu Glu
 275 280 285

Gly Glu Glu Ala Ser Lys Leu Tyr Pro Glu Val Asn Tyr Thr Arg Met
 290 295 300

Asp Glu Tyr Leu Lys Ile Tyr Val
 305 310

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 312 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Met Gly Lys Ser Lys Val Leu Val Val Gly Gly Thr Gly Tyr Val Gly
 1 5 10 15

Arg Arg Ile Val Lys Ala Ser Leu Glu His Gly His Glu Thr Phe Ile
 20 25 30

Leu Gln Arg Pro Glu Ile Gly Leu Asp Ile Glu Lys Leu Gln Ile Leu
 35 40 45

Leu Ser Phe Lys Lys Gln Gly Ala Ile Leu Val Glu Ala Ser Phe Ser
 50 55 60

Asp His Lys Leu Val Asp Ala Val Lys Leu Val Val Val Ile
65 70 75 80

Cys Thr Met Ser Gly Val His Phe Arg Ser His Asn Leu Leu Thr Gln
85 90 95

Leu Lys Leu Val Glu Ala Ile Lys Asp Ala Gly Asn Ile Lys Arg Phe
100 105 110

Leu Pro Ser Glu Phe Gly Met Asp Pro Ala Leu Met Gly His Ala Leu
115 120 125

Glu Pro Gly Arg Val Thr Phe Asp Glu Lys Met Thr Val Arg Lys Ala
130 135 140

Ile Glu Glu Ala Asn Ile Pro Phe Thr Tyr Ile Ser Ala Asn Cys Phe
145 150 155 160

Ala Gly Tyr Phe Ala Gly Asn Leu Ser Gln Met Lys Thr Leu Leu Pro
165 170 175

Pro Arg Asp Lys Val Leu Leu Tyr Gly Asp Gly Asn Val Lys Pro Val
180 185 190

Tyr Met Asp Glu Asp Asp Val Ala Thr Tyr Thr Ile Lys Thr Ile Asp
195 200 205

Asp Pro Arg Thr Leu Asn Lys Thr Val Tyr Leu Arg Pro Pro Glu Asn
210 215 220

Ile Leu Thr His Lys Glu Leu Ile Glu Lys Trp Glu Glu Leu Ile Gly
225 230 235 240

Lys Gln Leu Glu Lys Asn Ser Ile Ser Glu Lys Asp Phe Leu Ser Thr
245 250 255

Leu Lys Gly Leu Asp Phe Ala Ser Gln Val Gly Val Gly His Phe Tyr
260 265 270

His Ile Phe Tyr Glu Gly Cys Leu Thr Asn Phe Glu Ile Gly Glu Asn
275 280 285

Gly Glu Glu Ala Ser Glu Leu Tyr Pro Glu Val Asn Tyr Thr Arg Met
290 295 300

Asp Gln Tyr Leu Lys Val Tyr Val
305 310

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1218 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 48..1028

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

AATTCGGCAC GAGGAAAAGT AAACACTGCC ACAGCAAGAG TGTCAA ATG GGA GAG	56
Met Gly Glu	
1	
GGA AAA GGA AGA ATT TGT GTC ACT GGA GGC ACA GGA TTC CTT GGT TCA	104
Gly Lys Gly Arg Ile Cys Val Thr Gly Gly Thr Gly Phe Leu Gly Ser	
5 10 15	
TGG ATA ATC AAG AGC CTC CTT GAA CAT GGA TAT GCT GTT AAT ACC ACT	152
Trp Ile Ile Lys Ser Leu Leu Glu His Gly Tyr Ala Val Asn Thr Thr	
20 25 30 35	
ATA AGA TCT GAC CCA GGA CGC AAG AGA GAT GTT AGC TTC CTC ACA AAC	200
Ile Arg Ser Asp Pro Gly Arg Lys Arg Asp Val Ser Phe Leu Thr Asn	
40 45 50	
CTA CCT GGT GCA TCA GAA AAG CTT AAA ATT TTC AAC GCT GAT CTC AGC	248
Leu Pro Gly Ala Ser Glu Lys Leu Lys Ile Phe Asn Ala Asp Leu Ser	
55 60 65	
GAC CCA GAG AGT TTT GGT CCA GCA GTT GAG GGT TGT GTT GGA ATT TTT	296
Asp Pro Glu Ser Phe Gly Pro Ala Val Glu Gly Cys Val Gly Ile Phe	
70 75 80	
CAC ACT GCC ACC CCA ATT GAT TTT GCG GTG AAC GAG CCA GAG GAA GTG	344
His Thr Ala Thr Pro Ile Asp Phe Ala Val Asn Glu Pro Glu Glu Val	
85 90 95	
GTG ACC AAA AGA GCC ATT GAT GGA GCA CTA GGC ATA TTG AAA GCA GGC	392
Val Thr Lys Arg Ala Ile Asp Gly Ala Leu Gly Ile Leu Lys Ala Gly	
100 105 110 115	
CTA AAA GCA AAG ACT GTG AAG AGG GTT TAC ACT TCT AGC GCC TCC	440
Leu Lys Ala Lys Thr Val Lys Arg Val Val Tyr Thr Ser Ser Ala Ser	
120 125 130	
ACT GTT TCC TTC AGC AGC CTA GAA GAG AAA GAT GTG GTG GAT GAG AGT	488
Thr Val Ser Ser Leu Glu Glu Lys Asp Val Val Asp Glu Ser	
135 140 145	
GTT TGG AGT GAT GTG GAT TTG CTC AGG AGT GTG AAG CCT TTT AGT TGG	536
Val Trp Ser Asp Val Asp Leu Leu Arg Ser Val Lys Pro Phe Ser Trp	
150 155 160	
TCC TAT GCA GTT TCA AAG GTG TTG TCA GAG AAG GCA GTG CTT GAA TTT	584
Ser Tyr Ala Val Ser Lys Val Leu Ser Glu Lys Ala Val Leu Glu Phe	
165 170 175	
GGA GAA CAG AAT GGA TTG GAA GTT ACC ACT CTT GTG CTT CCT TTT GTT	632
Gly Glu Gln Asn Gly Leu Glu Val Thr Thr Leu Val Leu Pro Phe Val	
180 185 190 195	
GTT GGA CGC TTT GTT TGT CCC AAG CTT CCT GAT TCT GTT GAA AGA GCA	680
Val Gly Arg Phe Val Cys Pro Lys Leu Pro Asp Ser Val Glu Arg Ala	
200 205 210	
CTG CTT TTG GTG TTA GGC AAA AAG GAA GAA ATT GGT GTC ATT CGT TAC	728
Leu Leu Ile Leu Gly Lys Lys Glu Glu Ile Gly Val Ile Arg Tyr	
215 220 225	
CAT ATG GTA CAT GTG GAT GTG GCT AGA GCA CAT ATC TTC CTG CTT	776
His Met Val His Val Asp Asp Val Ala Arg Ala His Ile Phe Leu Leu	
230 235 240	

GAG CAT CCG C CCA AAA GGG AGA TAT AAT TGC TCA	TTC ATT GTG	824	
Glu His Pro Asn Pro Lys Gly Arg Tyr Asn Cys Ser	Pro Phe Ile Val		
245	250	255	
CCT ATT GAA GAG ATT GCT GAA ATT ATT TCA GCC AAA TAC CCA GAA TAT		872	
Pro Ile Glu Glu Ile Ala Glu Ile Ile Ser Ala Lys Tyr Pro Glu Tyr			
260	265	270	275
CAA ATA CCA GCA CTA GAA GAG GTG AAG GAA ATT AAA GGT GCC AAG TTA		920	
Gln Ile Pro Ala Leu Glu Glu Val Lys Glu Ile Lys Gly Ala Lys Leu			
280	285	290	
CCA CAT TTA ACC TCC CAG AAA CTT GTG GAT GCT GGT TTT GAG TTC AAG		968	
Pro His Leu Thr Ser Gln Lys Leu Val Asp Ala Gly Phe Glu Phe Lys			
295	300	305	
TAT AGC GTT GAG GAC ATA TTT ACG GAT GCA ATT GAA TGC TGC AAG GAA		1016	
Tyr Ser Val Glu Asp Ile Phe Thr Asp Ala Ile Glu Cys Cys Lys Glu			
310	315	320	
AAG GGT TAC CTT TAATCGATT TAGCCACGAA GTTGAAAAAA TAAAATTGTC		1068	
Lys Gly Tyr Leu			
325			
GAAGATGATT GTTAGTTCGT ACTATTTCA GATCCCTGGC AATGATGCC CTTGACATGT		1128	
ACTCCATTAA ATGCATGATG TTTTCTTAAT AAATTGACCA GGGAAATAAT TCTTTGGTT		1188	
TGTCTGAAAA AAAAAAAA AAAAACTCGA		1218	

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 327 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met	Gly	Glu	Gly	Lys	Gly	Arg	Ile	Cys	Val	Thr	Gly	Gly	Thr	Gly	Phe
1				5					10				15		
Leu	Gly	Ser	Trp	Ile	Ile	Lys	Ser	Leu	Leu	Glu	His	Gly	Tyr	Ala	Val
				20				25				30			
Asn	Thr	Thr	Ile	Arg	Ser	Asp	Pro	Gly	Arg	Lys	Arg	Asp	Val	Ser	Phe
			35			40				45					
Leu	Thr	Asn	Leu	Pro	Gly	Ala	Ser	Glu	Lys	Leu	Lys	Ile	Phe	Asn	Ala
			50			55				60					
Asp	Leu	Ser	Asp	Pro	Glu	Ser	Phe	Gly	Pro	Ala	Val	Glu	Gly	Cys	Val
			65			70			75			80			
Gly	Ile	Phe	His	Thr	Ala	Thr	Pro	Ile	Asp	Phe	Ala	Val	Asn	Glu	Pro
				85				90				95			
Glu	Glu	Val	Val	Thr	Lys	Arg	Ala	Ile	Asp	Gly	Ala	Leu	Gly	Ile	Leu
			100			105						110			
Lys	Ala	Gly	Leu	Lys	Ala	Lys	Thr	Val	Lys	Arg	Val	Val	Tyr	Thr	Ser
			115			120						125			

Ser Ala Ser Val Ser Phe Ser Ser Leu Glu Glu Asp Val Val
 130 135 140
 Asp Glu Ser Val Trp Ser Asp Val Asp Leu Leu Arg Ser Val Lys Pro
 145 150 155 160
 Phe Ser Trp Ser Tyr Ala Val Ser Lys Val Leu Ser Glu Lys Ala Val
 165 170 175
 Leu Glu Phe Gly Glu Gln Asn Gly Leu Glu Val Thr Thr Leu Val Leu
 180 185 190
 Pro Phe Val Val Gly Arg Phe Val Cys Pro Lys Leu Pro Asp Ser Val
 195 200 205
 Glu Arg Ala Leu Leu Leu Val Leu Gly Lys Lys Glu Glu Ile Gly Val
 210 215 220
 Ile Arg Tyr His Met Val His Val Asp Asp Val Ala Arg Ala His Ile
 225 230 235 240
 Phe Leu Leu Glu His Pro Asn Pro Lys Gly Arg Tyr Asn Cys Ser Pro
 245 250 255
 Phe Ile Val Pro Ile Glu Glu Ile Ala Glu Ile Ile Ser Ala Lys Tyr
 260 265 270
 Pro Glu Tyr Gln Ile Pro Ala Leu Glu Glu Val Lys Glu Ile Lys Gly
 275 280 285
 Ala Lys Leu Pro His Leu Thr Ser Gln Lys Leu Val Asp Ala Gly Phe
 290 295 300
 Glu Phe Lys Tyr Ser Val Glu Asp Ile Phe Thr Asp Ala Ile Glu Cys
 305 310 315 320
 Cys Lys Glu Lys Gly Tyr Leu
 325

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 326 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS:
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: protein
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Met Ala Glu Gly Lys Gly Arg Val Cys Val Thr Gly Gly Thr Gly Phe
 1 5 10 15
 Leu Gly Ser Trp Ile Ile Lys Ser Leu Leu Glu Asn Gly Tyr Ser Val
 20 25 30
 Asn Thr Thr Ile Arg Ala Asp Pro Glu Arg Lys Arg Asp Val Ser Phe
 35 40 45
 Leu Thr Asn Leu Pro Gly Ala Ser Glu Lys Leu His Phe Phe Asn Ala
 50 55 60
 Asp Leu Ser Asn Pro Asp Ser Phe Ala Ala Ile Glu Gly Cys Val
 65 70 75 80

Gly Ile Phs Thr Ala Ser Pro Ile Asp Phe Ala Ser Glu Pro
85 90 95

Glu Glu Ile Val Thr Lys Arg Thr Val Asp Gly Ala Leu Gly Ile Leu
100 105 110

Lys Ala Cys Val Asn Ser Lys Thr Val Lys Arg Phe Ile Tyr Thr Ser
115 120 125

Ser Gly Ser Ala Val Ser Phe Asn Gly Lys Asp Lys Asp Val Leu Asp
130 135 140

Glu Ser Asp Trp Ser Asp Val Asp Leu Leu Arg Ser Val Lys Pro Phe
145 150 155 160

Gly Trp Asn Tyr Ala Val Ser Lys Thr Leu Ala Glu Lys Ala Val Leu
165 170 175

Glu Phe Gly Glu Gln Asn Gly Ile Asp Val Val Thr Leu Ile Leu Pro
180 185 190

Phe Ile Val Gly Arg Phe Val Cys Pro Lys Leu Pro Asp Ser Ile Glu
195 200 205

Lys Ala Leu Val Leu Val Leu Gly Lys Lys Glu Gln Ile Gly Val Thr
210 215 220

Arg Phe His Met Val His Val Asp Asp Val Ala Arg Ala His Ile Tyr
225 230 235 240

Leu Leu Glu Asn Ser Val Pro Gly Gly Arg Tyr Asn Cys Ser Pro Phe
245 250 255

Ile Val Pro Ile Glu Glu Met Ser Gln Leu Leu Ser Ala Lys Tyr Pro
260 265 270

Glu Tyr Gln Ile Leu Thr Val Asp Glu Leu Lys Glu Ile Lys Gly Ala
275 280 285

Arg Leu Pro Asp Leu Asn Thr Lys Lys Leu Val Asp Ala Gly Phe Asp
290 295 300

Phe Lys Tyr Thr Ile Glu Asp Met Phe Asp Asp Ala Ile Gln Cys Cys
305 310 315 320

Lys Glu Lys Gly Tyr Leu
325

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 98/19553

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/82 C12N9/02 C12N9/90 C12N5/10 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TERAI, Y., ET AL. : "cloning and overexpression of the chalcone-flavanone isomerase cDNA from Pueraria lobata and its overexpression in Escherichia coli" EMBL SEQUENCE DATA LIBRARY, 15 August 1995, XP002090217 heidelberg, germany cited in the application accession no. D63577	1
X	SCOLNIK, P.A. AND BARTLEY, G.E.: "two members of an Arabidopsis geranylgeranyl pyrophosphate synthase gene family" EMBL SEQUENCE DATA LIBRARY, 23 March 1996, XP002090218 heidelberg, germany accession no. U48590	5
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 January 1999

Date of mailing of the international search report

17/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Holtorf, S

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/19553

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GUO, L. AND PAIVA, N.L.: "molecular cloning and expression of alfalfa (<i>Medicago sativa</i> L.) vestitone reductase, the penultimate enzyme in medicarpin biosynthesis" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 320, no. 2, July 1995, pages 353-360, XP002090219 see the whole document	16,17
X	WO 96 15239 A (SAMUEL ROBERTS NOBLE FOUNDATION) 23 May 1996 see example 1	16,17
A	PAIVA N L: "BIOTRANSFORMATION OF ISOFLAVONOIDS BY TRANSGENIC TOBACCO CELL CULTURES" ABSTRACTS OF PAPERS. ACS NATIONAL MEETING, no. 1/02, 2 April 1995, page 129 XP000571305 see the whole document	1-17
A	PAIVA N L ET AL: "STRESS RESPONSES IN ALFALFA (<i>MEDICAGO SATIVA</i> L.) 11 MOLECULAR CLONING AND EXPRESSION OF ALFALFA ISOFLAVONE REDUCTASE, A KEY ENZYME OF ISOFLAVONOID PHYTOALEXIN BIOSYNTHESIS" PLANT MOLECULAR BIOLOGY, vol. 17, no. 4, 1 October 1991, pages 653-667, XP000570444 see the whole document	1-17
P, X	SEEHAUS, K. AND TENHAKEN, R.: "cloning of genes by mRNA differential display associated with the hypersensitive reaction of soybean after inoculation with <i>Pseudomonas syringae</i> pv. <i>glycinea</i> " EMBL SEQUENCE DATA LIBRARY, 25 August 1998, XP002090220 heidelberg, germany accession no. AJ004902	1
P, X	SCHOPFER, C.R.: "unpublished" EMBL SEQUENCE DATA LIBRARY, 11 December 1997, XP002090221 heidelberg, germany accession no. AJ003246	9

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/19553

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9615239	A 23-05-1996	US 5750399 A	12-05-1998
		AU 699496 B	03-12-1998
		AU 3972795 A	06-06-1996
		CA 2204131 A	23-05-1996
		EP 0792356 A	03-09-1997
		JP 10508750 T	02-09-1998